%%[SET @subscriberkey = _subscriberKey]%%
%%[SET @content = emailname_ JobID]%%
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office">
<head>
<script runat="server" language="ampscript">ContentBlockbyId("260486")</script>
<meta charset="UTF-8">
<meta name="x-apple-disable-message-reformatting">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, minimum-scale=1, user-scalable=no">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="format-detection" content="telephone=no">
<meta name="format-detection" content="date=no">
<meta name="format-detection" content="address=no">
<meta name="format-detection" content="email=no">
<!--[if IE]><style>body,table,p,td,th,ul,li,div,span {mso-line-height-rule: exactly !important;} sup, sub {font-size: 80% !important;display: inline !important;line-height: 1em !important;vertical-align: top !important;} sub {vertical-align: bottom !important;} .outlook-wrap-all {word-break:break-all !important;}</style><![endif]-->
<!--[if mso]><style>table, td {  mso-table-lspace: 0pt; mso-table-rspace: 0pt; } .height_mob{mso-height: auto !important;}</style><![endif]-->
<!--[if gte mso 12]><style>sup, sub {font-size: 100% !important;vertical-align: top !important;display: inline !important;} sup, sub {mso-text-raise: 0.15em;} </style><![endif]-->
<!--[if gte mso 9]><style>li {text-indent: -1em; text-align:-webkit-match-parent; display:list-item;} } </style><![endif]-->
<style>
* {word-break: break-word;}
td, th, p{
        mso-hyphenate: none;
    }
.tap-arrows{
    display: block;
}
.hide {display: none;}
.image {max-width: 100% !important;}
p {margin: 0;}
.outlook_wrap_all {word-break: break-all;}
th {font-weight: normal;}
sub,sup {line-height: 0px !important;}
.button {box-sizing: border-box !important;}
.mobile_img {display: none}

@media screen and (max-width: 599px),
yahoo and (max-width: 480px),
print and (max-width: 552px) {
* {box-sizing: border-box;-webkit-text-size-adjust: none;text-size-adjust: none;}
html,body {width: 100vw;}
body {margin: 0px !important;padding: 0px !important;font-family: Arial, Helvetica, sans-serif;color: #555555;}
.device_width,.brand_cell,.preheader_cell,.footer_cell,.ves_cell,.merckconnect_cell {width: 100% !important;display: table;}
.veeva_header img,.header img,.main_body img,.mobile_settings img {display: inline-block !important;margin-bottom: 0;vertical-align: middle;}
.display_block img {display: block !important;}
.display_block img.mobile_img {display: block !important;height: auto;}
.image_mobile img.desktop_img {display: none !important;}
.col_valign--top {vertical-align: top;}
.col_valign--middle {vertical-align: middle;}
.col_valign--bottom {vertical-align: bottom;}
.veeva_header .columns .image,.header .columns .image,.main_body .columns .image {text-align: center;vertical-align: middle;}
.main_body .columns .image.notNested.image_align__left {text-align: left;vertical-align: middle;}
.main_body .columns .image.notNested.image_align__center {text-align: center;vertical-align: middle;}
.main_body .columns .image.notNested.image_align__right {text-align: right;vertical-align: middle;}
.reference p {line-height: 1em !important;}
.columns th {width: 100% !important;display: block !important;}
.columns_mobile .column__parent {height: 20px !important;}
.columns_mobile .cell {height: auto !important;}
.columns_mobile td table {width: 100% !important;height: 100%;}
th.cell {height: inherit !important;}
.cell--empty {display: none !important;}
/* Veeva Email Specific */
.vu-footer-col__icon {width: 35% !important;}
.vu-footer-col__icon img {width: 100% !important;}
.vu-footer-col__text {width: 65% !important;}
.vu-footer-col__text .body_copy {font-size: 16px !important;line-height: 22px !important;padding-bottom: 15px !important;}
/* PDF Spacer */
.wrapper {padding-bottom: 50px;}
/* mobile class css */
.image__width--25 img,.mobile__width--25,.column__width--25 {width: 25% !important;}
.image__width--40 img,.mobile__width--40,.column__width--40 {width: 40% !important;}
.image__width--47 img,.mobile__width--47,.column__width--47 {width: 47% !important;}
.image__width--55 img,.mobile__width--55,.column__width--55 {width: 55% !important;}
.image__width--55-7 img,.mobile__width--55-7,.column__width--55-7 {width: 55.7% !important;}
.image__width--60 img,.mobile__width--60,.column__width--60 {width: 60% !important;}
.image__width--100 img,.mobile__width--100,.column__width--100 {width: 100% !important;}
.mobile__align--left {text-align: left !important;}
.mobile__align--center {text-align: center !important;}
.mobile__align--right {text-align: right !important;}
.pleft {padding-left: 12px;}
.fs24_lh32 {font-size: 24px !important;line-height: 32px !important;}
.pd20 {padding: 20px !important;}
.pdlr20 {padding-left: 20px !important;padding-right: 20px !important;}
.pdlr0 {padding-left: 0px !important;padding-right: 0px !important;}
.pdt10 {padding-top: 10px !important;}
.pdb10 {padding-bottom: 10px !important;}
.wd32{width: 132px !important;}
.mob_img {width: 100px !important;}
}
</style>
<style>
body::-webkit-scrollbar {width: 0;}
.media420{display: none !important;}
@media screen and (max-width:736px),
yahoo and (max-width:480px),
print and (max-width:552px) {
.device_width {width: 100% !important;display: table}
}
.expanded-row-content {border-top: none;display: grid;grid-column: 1/-1;justify-content: flex-start;color: #AEB1B3;font-size: 13px;background-color: #fff}
.hide-row {display: none}
</style>
<style type="text/css">
.ReadMsgBody {width: 100%}
.ExternalClass {width: 100%}
.ExternalClass * {line-height: 100%}
div,p,a,li,td {-webkit-text-size-adjust: none;-ms-text-size-adjust: none}
TD IMG {display: initial;border: 0}
table {mso-table-lspace: 0pt;mso-table-rspace: 0pt}
a:link {color: #000001;text-decoration: none}
a:active {color: #000001;text-decoration: none}
a:visited {color: #000001;text-decoration: none}
a:hover {color: #000001;text-decoration: none}
textarea {resize: none}
textarea:focus,input:focus {outline: none}
body {margin: 0;font-family: Arial, Helvetica, sans-serif}
.appleLinks a {color: inherit !important;text-decoration: none}
@-ms-viewport {width: device-width}

@media only screen and (max-width: 480px) {
body[yahoo] .container {width: 100% !important}
body[yahoo] .mobile-hidden {display: none !important}
body[yahoo] .photo {width: 100% !important;height: auto !important}
body[yahoo] .mobile-padding {padding-right: 20px !important;padding-left: 20px !important}
body[yahoo] .drop {width: 100% !important;float: left !important}
body[yahoo] .left {float: left !important}
body[yahoo] .text-left {text-align: left !important}
body[yahoo] .logo {width: 100px !important;height: auto !important}
body[yahoo] .show {display: block !important;margin: 0 !important;padding: 0 !important;overflow: visible !important;width: 100% !important;max-height: inherit !important}
body[yahoo] .footer-logo {width: 95px !important;height: auto !important}
body[yahoo] .padding15 {padding-top: 15px !important;padding-bottom: 15px !important}
body[yahoo] .padding20 {padding-top: 20px !important;padding-bottom: 20px !important}
body[yahoo] .padding0 {padding: 0 !important}
body[yahoo] .paddingtop0 {padding-top: 0px !important}
body[yahoo] .paddingtop10 {padding-top: 10px !important}
body[yahoo] .paddingtop15 {padding-top: 15px !important}
body[yahoo] .paddingtop20 {padding-top: 20px !important}
body[yahoo] .paddingright20 {padding-right: 20px !important}
body[yahoo] .paddingbottom0 {padding-bottom: 0px !important}
body[yahoo] .paddingbottom10 {padding-bottom: 10px !important}
body[yahoo] .paddingbottom15 {padding-bottom: 15px !important}
body[yahoo] .paddingbottom20 {padding-bottom: 20px !important}
body[yahoo] .paddingleft0 {padding-left: 0px !important}
body[yahoo] .paddingleft20 {padding-left: 20px !important}
body[yahoo] .cta {width: 100% !important}
body[yahoo] .hidden {display: none !important}
body[yahoo] .center {margin: 0 auto}
body[yahoo] .text-center {text-align: center !important}
body[yahoo] .ctafix {line-height: 18px !important;padding-top: 10px !important;padding-bottom: 10px !important}
body[yahoo] .font20 {font-size: 20px !important;line-height: 24px !important}
body[yahoo] .font15 {font-size: 15px !important;line-height: 19px !important}
body[yahoo] .font18 {font-size: 18px !important;line-height: 22px !important}
body[yahoo] .font14 {font-size: 14px !important;line-height: 18px !important}
body[yahoo] .font13 {font-size: 13px !important;line-height: 17px !important}
body[yahoo] .width50 {width: 50px !important;height: auto !important}
body[yahoo] .width70 {width: 70px !important;height: auto !important}
body[yahoo] .width15 {width: 15px !important;height: auto !important}
.pdr30{padding-right: 0px !important;}
}

@media yahoo,
only screen and (min-width:0) {
body[yahoo] .mj-accordion-element {display: block}
input.mj-accordion-checkbox,.mj-accordion-less {display: none !important}
#Kinetic:checked~* .staticacc {display: block !important;}
#Kinetic:checked~* .staticaccContact {display: none !important;}
#slideSSI:checked+table~* .outerSSI {display: none !important;}
input.mj-accordion-checkbox2:checked+* .staticacc {display: block !important;}
input.mj-accordion-checkbox+* .mj-accordion-title {touch-action: manipulation;-webkit-user-select: none;-moz-user-select: none;user-select: none}
input.mj-accordion-checkbox+* .mj-accordion-content {overflow: hidden;display: none}
input.mj-accordion-checkbox+* .mj-accordion-more {display: block !important}
input.mj-accordion-checkbox:checked+* .mj-accordion-content {display: block}
input.mj-accordion-checkbox:checked+* .mj-accordion-expand {display: none}
input.mj-accordion-checkbox:checked+* .mj-accordion-more {display: none !important}
input.mj-accordion-checkbox:checked+* .mj-accordion-less {display: block !important}
#slide-1:checked+table .slide1-content {display: initial !important;}
#slide-1+table .slide1-content {display: initial;}
#slide-2:checked+table .slide2-content {display: initial !important;}
#slide-2+table .slide2-content {display: initial;}
#slide-3:checked+table .slide3-content {display: initial !important;}
#slide-3+table .slide3-content {display: initial;}
#slide-4:checked+table .slide4-content {display: initial !important;}
#slide-4+table .slide4-content {display: initial;}
#slide-5+table .slide5-content {display: initial;}
#slide-5:checked+table .slide5-content {display: initial !important;}
#slide-6+table .slide6-content {display: initial;}
#slide-6:checked+table .slide6-content {display: initial !important;}
#slide0:checked+table .slide1-content {display: none;}
#slide0:checked+table .slide2-content {display: none;}
#slide0:checked+table .slide3-content {display: none;}
#slide0:checked+table .slide4-content {display: none;}
#slide0:checked+table .slide5-content {display: none;}
#slide0:checked+table .slide6-content {display: none;}
#slide0:checked+table .slide-space {display: none;}
#slide0:checked+table .innerSSI {display: none !important;}
#slideSSI:checked+table .outerSSI {display: block !important;}
#slideSSI:checked+table .outerCon {display: none !important;}
#slide0:checked+table .slide-bottom {display: initial !important;}
#Kinetic:checked~* .interactBorder {background: #ffffff;border: 1px solid #BEBEBE;border-radius: 8px 8px 8px 8px;}
#Kinetic:checked~* .incTab{display: inline-block !important;}
}
</style>
<style>
@media screen and (-webkit-min-device-pixel-ratio: 0) {


}
body {margin: 0px;padding: 0px;}
a img {border: none !important;}
table {mso-table-lspace: 0pt;mso-table-rspace: 0pt;}
.yahoo {display: none;}
.slide1-content,.slide2-content,.slide3-content {font-size: 20px;line-height: 25px;font-family: Arial, Helvetica, sans-serif;}
.slide1-content td,.slide2-content td,.slide3-content td,.slide4-content td,.slide5-content td,.slide6-content td {padding:0px;}
#CarouselWrapper {width: 460px!important;display: table;overflow: hidden;}
.CarouselMain {width: 460px!important;}
.button {border-radius: 100px;visibility: visible !important;width: 108px !important;display: block !important;text-align: center;z-index: 7;box-sizing: content-box;color: #ffffff !important;font-family: Arial, Helvetica, sans-serif;font-size: 13px !important;line-height: 16px !important;font-weight: bold;cursor: pointer;}
.button1{border-radius: 100px;visibility: visible !important;width: 65px !important;display: block !important;text-align: center;z-index: 7;box-sizing: content-box;color: #ffffff !important;font-family: Arial, Helvetica, sans-serif;font-size: 13px !important;line-height: 16px !important;font-weight: bold;cursor: pointer;}
@media screen and (max-width:736px),
yahoo and (max-width:480px),
print and (max-width:552px) {

#CarouselWrapper,.CarouselMain {width: 100% !important;}
.slide1-content,.slide2-content,.slide3-content,.slide4-content,.slide5-content,.slide6-content{top: 0px;width: 100% !important;background-repeat: no-repeat;font-size: 20px;line-height: 25px;font-family: Arial, Helvetica, sans-serif;}
.button {max-height: 50px !important;border: none;}
.mob_width{width: auto;}
.mob_align{vertical-align: text-bottom;}
.fs20_lh25{font-size: 20px !important;line-height: 25px !important;}
.fs18_lh24{font-size: 18px !important;line-height: 24px !important;}
.padding_right{padding-right: 5px !important;}
.mob_alignarrow{width: 35%;float: right;padding: 10px 0px;}
.mob_alligntext{width: 62%;line-height: 20px !important;float: left;}
.mobilebg{background-image: url(https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subheader.png) !important;background-size: 100% 100% !important;}
.mobilebg2{background-image: url(https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Mobile_Subhead_Background.png) !important;background-size: 100% 100% !important;}
th.tableCell{display: table-cell !important}
th.wid22{width: 22px !important;}
th.wid194{width: 194px !important}
.lnht10{height: 10px !important;font-size: 10px !important;line-height: 10px !important;}
.lnht11{height: 11px !important;font-size: 11px !important;line-height: 11px !important;}
.lnht15{height: 15px !important;font-size: 15px !important;line-height: 15px !important;}
.lnht8{height: 8px !important;font-size: 8px !important;line-height: 8px !important;}
.lnht18{height: 18px !important;font-size: 18px !important;line-height: 18px !important;}
.lnht20{height: 20px !important;font-size: 20px !important;line-height: 20px !important;}
.lnht22{height: 22px !important;font-size: 22px !important;line-height: 22px !important;}
.lnht24{height: 24px !important;font-size: 24px !important;line-height: 24px !important;}
.lnht25{height: 25px !important;font-size: 25px !important;line-height: 25px !important;}
.lnht27{height: 27px !important;font-size: 27px !important;line-height: 27px !important;}
.lnht30{height: 30px !important;font-size: 30px !important;line-height: 30px !important;}
.lnht35{height: 35px !important;font-size: 35px !important;line-height: 35px !important;}
.d-none{display: none !important;}
.lnht5{line-height: 5px !important;height:5px !important;font-size: 5px !important;}
td.mob_align.text-left{text-align: left !important;}
td.text-right{text-align: right !important;}
td.wid110{width: 110px !important;}
.wid75{width:75px !important}
.bnrpd{padding: 20px 20px 0px 22px !important;}
.bnrpd-mobi{padding: 5px 20px 18px 22px !important;}
.bnrpd-mobi2{padding: 0px 20px 18px 22px !important;}
.pt20{padding-top: 20px !important;}
.pt0{padding-top: 0 !important;}
.pb0{padding-bottom: 0 !important;}
.pb20{padding-bottom: 20px !important;}
.column__width--475{width:47.5% !important}
.pr10{padding-right: 12px !important;}
.pl10{padding-left: 12px !important;}
.wid41{width:41% !important}
.padslide1{padding:24px 24px 0px 24px !important;}
.pdb0{padding-bottom: 0 !important;}
.pdL10{padding-left: 10px !important;}
.pdR10{padding-right: 10px !important;}
.wid120{width:120px !important}
.fs17_lh20{font-size: 17px !important;line-height: 20px !important;}
.pdL20{padding-left: 20px !important;}
.pdR20{padding-right: 20px !important;}
.pdT15{padding-top: 15px !important;}
.pdT19{padding-top: 19px !important;}
.pdT20{padding-top: 20px !important;}
.pdT22{padding-top: 22px !important;}
.pdT25{padding-top: 25px !important;}
.pdT28{padding-top: 28px !important;}
.pdB20{padding-bottom: 20px !important;}
.pdL15{padding-left: 15px !important;}
.pdR15{padding-right: 15px !important;}
.pdB15{padding-bottom: 15px !important;}
.fs14_lh20{font-size: 14px !important;line-height: 20px !important;}
.fs12_lh20{font-size: 12px !important;line-height: 20px !important;}
.bnrtext1pd{padding: 21px 10px 9px 10px !important}
.pbnrscrollpd{padding: 9px 10px 1px 10px !important}
th.disp_table{display: table-cell !important;}
.wd32{width: 132px !important;}
.d-block{display: block !important;}
th.isNested.wid215.disp_table.wid215{width:215px !important}
.pdT0{padding-top: 0 !important;}
.wid100{width:100% !important}
th.device_width.spacer.d-none.visitMerck{display: none !important;}
.max-wid89{max-width: 88% !important;}
.max-wid55{max-width: 55% !important;}
.responMobi{display: block !important;width:100% !important}
.wid260{width:250px !important}.height20{height: 20px !important;}
.mobHeight{height:614px !important}

}
@media screen and (max-width:420px){
.media420{display: block !important;}
table.mobHeightmedia{height:614px !important}
td.spacer.media420 {height: 65px !important;line-height: 65px !important;}
.pdright{padding-right: 10px;}
}
</style>
<style>
@media yahoo {
.button {line-height: 50px !important;}}
</style>
<style>
*[x-apple-data-detectors],
/* iOS */
.x-gmail-data-detectors,
/* Gmail */
.x-gmail-data-detectors * {border-bottom: 0 !important;cursor: default !important;color: inherit !important;text-decoration: none !important;font-size: inherit !important;font-family: inherit !important;font-weight: inherit !important;line-height: inherit !important;}
</style>

<!--[if gte mso 9]>
<xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
<o:PixelsPerInch>96</o:PixelsPerInch>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<style> @media print{ #_two50 { background-image:url('https://2merck.everestengagement.com/ea/rL7XYGpnkw/?t=p&e=%%_SubscriberKey%%&c=%%emailname_%%'); } } blockquote #_two50, #mailContainerBody #_two50, div.OutlookMessageHeader, table.moz-email-headers-table { background-image:url('https://2merck.everestengagement.com/ea/rL7XYGpnkw/?t=f&e=%%_SubscriberKey%%&c=%%emailname_%%'); } </style>
<style data-name="interactive" data-ignore-inlining>

#Kinetic:checked ~* .flex-container {height:330px !important;}
@media only screen and (max-width: 600px) { 
#Kinetic:checked ~* .flex-container {height:435px !important;}
}
#Kinetic:checked ~* .controls {display: flex;flex-direction: row;justify-content:center;align-items: center;gap: 20px;margin: 16px 0;position: relative;height: auto;opacity: 1;width: 100%;}
#Kinetic:checked~* .staticacc {display: block !important;}
</style>
<style data-name="interactive" data-ignore-inlining>
/* SSI Toggle */
.toggleContainer {position: relative;}
.toggle1 {position: absolute;right: 5px;top: 10px;}
.toggle2 {position: absolute;right: 10px;top: 10px;}
#Kinetic:checked~* #ClosedSSI:checked~#closedSSI {display: inline-block !important;}
input.mj-accordion-checkbox:checked+* .mj-accordion-content {display: block !important;background-image:url('%%=CloudPagesURL(30134, 'subscriberkey', @subscriberkey, 'emailName', @content, 'actionID', 'expandSSI')=%%')}
</style>
<style data-name="interactive" data-ignore-inlining >
#Kinetic:checked~* .interactive {display: block !important;}
#Kinetic:checked~* .fallback {display: none !important;}
#Kinetic:checked~* .& .fallback {display: block !important;}
#Kinetic:checked~* .& .interactive {display: none !important;}
#Kinetic:checked ~* .legalBG {background-color:#F1F1F1 !important;}
/* Reordering */
#Kinetic:checked ~* #One, 
#Kinetic:checked ~* #Two, 
#Kinetic:checked ~* #Three, 
#Kinetic:checked ~* #Four, 
#Kinetic:checked ~* #legal1,
#Kinetic:checked ~* #legal2,
#Kinetic:checked ~* #legal3,
#Kinetic:checked ~* #legal4,
#Kinetic:checked ~* #legal5,
#Kinetic:checked ~* #legal6 {display:none;}

/* Reording the content cards with caption-side, then showing the carousel slide that is currently selected, while hiding the others */
#slide-1:checked+table .slide1-content {display: initial !important;caption-side: top !important;background-image:url('%%=CloudPagesURL(30134, 'subscriberkey', @subscriberkey, 'emailName', @content, 'actionID', 'Slide1 RCC')=%%')}
#slide-2:checked+table .slide2-content {display: initial !important;caption-side: top !important;background-image:url('%%=CloudPagesURL(30134, 'subscriberkey', @subscriberkey, 'emailName', @content, 'actionID', 'Slide2 NMIBC‍')=%%')}
#slide-3:checked+table .slide3-content {display: initial !important;caption-side: top !important;background-image:url('%%=CloudPagesURL(30134, 'subscriberkey', @subscriberkey, 'emailName', @content, 'actionID', 'Slide3 NSCLC‍')=%%')}
#slide-4:checked+table .slide4-content {display: initial !important;caption-side: top !important;background-image:url('%%=CloudPagesURL(30134, 'subscriberkey', @subscriberkey, 'emailName', @content, 'actionID', 'Slide4 TNBC‍')=%%')}
#slide-5:checked+table .slide5-content {display: initial !important;caption-side: top !important;background-image:url('%%=CloudPagesURL(30134, 'subscriberkey', @subscriberkey, 'emailName', @content, 'actionID', 'Slide5 melanoma')=%%')}

#Kinetic:checked ~ *.& #One, 
#Kinetic:checked ~* .& #Two, 
#Kinetic:checked ~* .& #Three, 
#Kinetic:checked ~* .& #Four, 
#Kinetic:checked ~* .& #legal1,
#Kinetic:checked ~* .& #legal2,
#Kinetic:checked ~* .& #legal3,
#Kinetic:checked ~* .& #legal4,
#Kinetic:checked ~* .& #legal5,
#Kinetic:checked ~* .& #legal6 {display:block !important;}
.& .controls {display:none !important;}
</style>
</head>
<body bgcolor="#FFFFFF" style="padding:0; margin:0px;">
<!--[if !mso]><!-->
<input type="checkbox" class="kinetic" name="interactive" id="Kinetic" style="position:fixed;display: none;" checked >
<!--<![endif]-->
<div style="display:none;font-size:1px;color:#333333;line-height:1px;max-height:0px;max-width:0px;opacity:0;overflow:hidden;"></div>

<div style="display: none; max-height: 0px; overflow: hidden;">&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;</div>
<table class="" width="100%" height="100%" cellspacing="0" cellpadding="0" border="0" align="center"
style="min-width:100%; min-height:100%; background-color:#FFFFFF;">
<tbody>
<tr>
<td class="topPadding" style="" align="center">
<center>
<table class="above_header device_width" width="660" cellspacing="0" cellpadding="0" border="0"
align="center" style="margin:0 auto; ">
<tbody>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px; background-color: #ffffff;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr>
<th class="device_width cell preheader" align="left" valign="top"
height="15"
style="border-radius: 0px 0px 0px 0px; width:600px;height:15px;padding:16px 20px 0px 20px; word-break:break-word; font-weight:normal;">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:13.2px; text-align:left;color: #444444;margin:0">
<span style="font-family: Arial,  Helvetica,  sans-serif;">%%=v(@PreHeader)=%%</span>
</p>
</th></tr></tbody></table></td></tr></tbody></table>
<table class="header device_width" width="660" cellspacing="0" cellpadding="0" border="0" align="center" style="margin:0 auto; ">
<tbody>
<tr>
<td class="layout columns_mobile" style="border-radius: 0px 0px 0px 0px;padding:0px 12px 0px 20px;background-color: #ffffff;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr><th class="device_width spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</tbody>
</table>
</td>
</tr>
<tr>
<th class="device_width cell subhead" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:18px; text-align:left;color: #006EAD;margin:0">
<span style="font-family: Arial,  Helvetica,  sans-serif; font-weight: 600; color: #006EAD;"><a href="https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf?UTM_term=TopPI" target="_blank" alias="Prescribing Information" style="color: #006EAD;">Prescribing Information</a></span>
</p>
</th>
</tr>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr><th class="device_width spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</tbody>
</table>
</td>
</tr>

<tr>
<td class="column__width--55-7 column__height--100 cell image  isNested"
align="left" valign="middle"
style="width:484px;height:60px;padding:0px 0px 18px 0px;border-radius: 0px 0px 0px 0px;">
<img class="desktop_img Brand mob_img" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Keytruda-Logo.png" title="KEYTRUDA® (pembrolizumab) Injection 100 mg" alt="KEYTRUDA® (pembrolizumab) Injection 100 mg" width="191" style="width:191px !important; display:block; max-width:100%;font-size: 8px !important;line-height: 8px !important;">
</td>

<th class=" column__height--100 cell isNested wd32" align="right" valign="middle" height="" style="width:100px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" height="" cellpadding="0" border="0">
<tr><td style="height:10px;">&nbsp;</td></tr>
<tr><td valign="middle" align="right" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a href="https://www.askmerck.com/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<span valign="middle" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">Ask Merck</span></a></td></tr>
<tr><td style="height:30px;">&nbsp;</td></tr>
</table>
</th>
<th class=" column__height--100 cell isNested" align="right" valign="middle" height="" style="width:36px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><td style="height:10px;">&nbsp;</td></tr>
<tr>
<td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a href="https://www.askmerck.com/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%" target="_blank" alias="Ask Merck" title="Ask Merck" style="text-decoration: none !important;"><img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a></td></tr>
<tr><td style="height:30px;">&nbsp;</td></tr>
</table></th></tr></tbody></table></td></tr></tbody>
</table>
<table class="main_body device_width" width="660" cellspacing="0" cellpadding="0" border="0" align="center" style="margin:0 auto;"><tbody>
<tr><th class="device_width spacer" height="" width="660" style="width: 660px;height:2px;font-size:2px;line-height:2px;border:0px;padding:0px; border-bottom: 1px solid #808285; background-color: #ffffff;">&nbsp;</th></tr>
<tr>
<td class="cell ssi_headline staticacc interactive" align="left" valign="top" style="display: none; border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
<tr><th class="spacer lnht15 layout columns" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[if !mso] --> 
<tr>
<td class="cell ssi_headline fallback" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color:#F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
<tr><th class="spacer layout columns lnht15" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[endif]-->
<!-- Hero image -->
<tr><th class="layout columns pdL20 pdR20" style="border-radius: 0px 0px 0px 0px;padding:0px 30px 0px 30px;background-color: #F1F1F1;">
<table width="100%" class="mobilebg" cellspacing="0" cellpadding="0" border="0" style="background-image: url('https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Header.png'); background-position:center center;background-repeat:no-repeat;background-size:100% 100%;">

<tr>
<th class="column__parent device_width" style="width: 600px;font-weight:normal;">
<!--[if gte mso 9]>
<v:rect xmlns:v="urn:schemas-microsoft-com:vml" fill="true" stroke="false" style="width:610px;height:164px;padding:0px 0px 0px 0px align:center;margin:0 auto;">
<v:fill type="frame" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Header.png" />
<v:textbox inset="0,0,0,0">
<![endif]-->

<tr>
<td style="padding:0px 0px 0px 0px" class="">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<th class="device_width cell subhead_large fs17_lh20 bnrtext1pd" align="center" valign="middle" style="border-radius: 0px 0px 0px 0px; width:600px;padding:29px 30px 30px 30px; word-break:break-word; font-weight:normal;"><p class="fs17_lh20" style="font-family: Arial, Helvetica, sans-serif;font-size: 30px; line-height:38px; text-align:center;color: #ffffff;margin:0">
Learn More About<br style="display: none;" class="d-block">&nbsp;These FDA-Approved Indications for&nbsp;KEYTRUDA</p></th></tr>
<tr>
<td class="" style="padding: 0px 0px 0px 0px;" align="center" valign="middle">
<table width="29%" class="wid40" border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; "><tbody>

</tbody></table></td></tr>
<tr>
<th class="device_width cell subhead_large fs12_lh20 pbnrscrollpd" align="center" valign="middle" style="border-radius: 0px 0px 0px 0px; width:600px;padding:3px 30px 5px 30px; word-break:break-word; font-weight:normal;"><p class="fs12_lh20" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:20px; text-align:center;color: #ffffff;margin:0">SCROLL TO SEE <span class="incTab" style="display:none;">INTERACTIVE&nbsp;</span>CONTENT BELOW.</p></th></tr></table></td></tr>
<!--[if gte mso 9]>
</v:textbox>
</v:rect>
<![endif]-->
</th></tr></table></th></tr>
<tr>
<td class="cell ssi_headline staticacc interactive" align="left" valign="top" style="display: none; border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
<tr><th class="spacer lnht15 layout columns" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[if !mso] --> 
<tr>
<td class="cell ssi_headline fallback" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
<tr><th class="spacer layout columns lnht15" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[endif]-->
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;"><tbody>
<tr><th class="device_width cell ssi_headline pd20 pt0 pdb0" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 30px 0px 30px; word-break:break-word; font-weight:normal;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 8px 8px 8px 8px; padding:24px 24px 24px 24px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><td class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
<!-- Accordion Section starts -->
<div style="background-color: white;">
<!--[if mso | IE]>
<table
align="center" border="0" cellpadding="0" cellspacing="0" class="" style="width:570px;" width="570">
<tr>
<td style="line-height:0px;font-size:0px;mso-line-height-rule:exactly;">
<![endif]-->
<div style="background:#ffffff;background-color:#ffffff;margin:0px auto;width:100%;">
<table align="center" border="0" cellpadding="0" cellspacing="0" role="presentation" style="background:#ffffff;background-color:#ffffff;width:100%;"><tbody>
<tr><td class="mobile_padding" style="direction:ltr;font-size:0px;padding:0px 0px 0px 0px;text-align:center;">
<!--[if mso | IE]>
<table role="presentation" border="0" cellpadding="0" cellspacing="0">
<tr><td class="" style="vertical-align:top;width:570px;">
<![endif]-->
<div class="mj-column-per-100 mj-outlook-group-fix" style="font-size:0px;text-align:left;direction:ltr;display:inline-block;vertical-align:top;width:100%;">
<table border="0" cellpadding="0" cellspacing="0" role="presentation" style="vertical-align:top;" width="100%">
<tbody><tr><td style="font-size:0px;padding:0px;word-break:break-word;">
<!--[if !mso | IE]><!-->
<input class="mj-accordion-checkbox2" type="checkbox" checked="checked" style="display:none;" id="accordion2">
<!--<![endif]-->
<table cellspacing="0" cellpadding="0" class="mj-accordion" style="width:100%;border-collapse:collapse;border:none;border-bottom:none;font-family:Ubuntu, Helvetica, Arial, sans-serif;">
<tbody><tr><td style="padding:0px;">

<!--[if !mso | IE]><!-->
<input class="mj-accordion-checkbox" type="checkbox" style="display:none;" id="accordion">
<!--<![endif]-->
<div>
<div class="mj-accordion-title">
<table cellspacing="0" cellpadding="0" style="width:100%;border-bottom:none;"><tbody>
<tr><td class="device_width cell ssi_headline pdr30" align="left" valign="center" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 15px 0px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 22px; line-height:24px; text-align:left;color: #2C6D3C;margin:0">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #006EAD; font-weight: 500;">Selected Safety Information</span></p></td>
<!--[if !mso | IE]><!-->
<td class="mj-accordion-ico" style="padding:0px 0px 15px 0px;vertical-align:middle;" width="32">
<label class="mj-accordion-element" style="font-size:13px;" for="accordion">
<span class="mj-accordion-more" style="display:none;width:32px;height:32px;font-size:3px; line-height:25px;font-family:Arial, Helvetica, sans-serif;color:#231F20;">
<img class="desktop_img" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/plus_icon-new.png" title="Plus Icon" alt="Plus Icon" width="32" height="32" style="display:block; max-width:100%;font-size: 5px !important;line-height: 5px !important;">
</span>
<span class="mj-accordion-less" style="display:none;width:32px;height:32px;font-size:3px; line-height:25px;font-family:Arial, Helvetica, sans-serif;color:#231F20;">
<img class="desktop_img" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/minus-icon.png" title="Minus Icon" alt="Minus Icon" width="32" height="32" style="display:block; max-width:100%;font-size: 5px !important;line-height: 5px !important;">
</span></label>
</td>
<!--<![endif]-->
</tr></tbody></table></div>
<div class="mj-accordion">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<th class="device_width cell ssi_subhead" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 30px 12px 0px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000;margin:0">
<strong style="font-family: Arial,  Helvetica,  sans-serif;">Severe
and
Fatal
Immune-Mediated
Adverse
Reactions</strong></p></th></tr></table></td></tr>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="17" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#2C6D3C;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000;">
KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that
bind to either the programmed death receptor-1 (PD-1) or the programmed
death ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby
removing inhibition of the immune response, potentially breaking
peripheral tolerance and inducing immune-mediated adverse reactions.
Immune-mediated adverse reactions, which may be severe or fatal, can
occur in any organ system or tissue, can affect more than one body
system simultaneously, and can occur at any time after starting
treatment or after discontinuation of treatment. Important
immune-mediated adverse reactions listed here may not include all
possible severe and fatal immune-mediated adverse reactions. </span></td></tr></tbody></table></th></tr>
<!--[if !mso]><!-->
<tr>
<td class="layout columns mj-accordion-expand staticacc interactive" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px; display: none;">
<label class="mj-accordion-element" style="font-size:13px;" for="accordion"><table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><td class="layout columns mj-accordion-expand" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<th class="device_width cell ssi_subhead" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:15px 30px 0px 0px; word-break:break-word; font-weight:normal;">
<!--[if mso]>
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 1px; line-height:1px; text-align:left;color: #006EAD;margin:0">
<strong style="font-family: Arial,  Helvetica,  sans-serif;"></strong>
</p>
<![endif]-->

<!--[if !mso] -->

<p style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:20px; text-align:left;color: #006EAD;margin:0;">
<strong style="font-family: Arial,  Helvetica,  sans-serif;">Expand to See Selected Safety Information</strong>
</p>

<!--[endif]-->
</th></tr>
</table></td></tr></table></label></td></tr>
<!--<![endif]-->
</tbody></table></td></table>
</div>
<div class="mj-accordion-content">
<table cellspacing="0" cellpadding="0" style="width:100%;border-bottom:none;">
<tbody>
<tr><td class="fs11" align="left" valign="top" style="font-size:16px; line-height:22px;font-family:Arial, Helvetica, sans-serif;color:#000;padding:0px 0px 0px 15px;text-align: justify;"></td></tr></tbody>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:10px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="17" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#2C6D3C;padding-bottom: 10px;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000;">
Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of anti&#08211;PD&zwj;-&zwj;1&zwj;/PD&zwj;-&zwj;L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. For patients with triple-negative breast cancer (TNBC) treated with KEYTRUDA in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.</span>
</td></tr>
<tr style="padding:0px 0px 0px 0px;">
<td class="list_item_0" align="left" valign="top" width="17" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px;">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#2C6D3C;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000;">
Withhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2&zwj;&nbsp;&zwj;mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.</span>
</td></tr></tbody></table></th></tr>
<!--[if !mso]><!-->
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<label class="mj-accordion-element" style="font-size:13px;" for="accordion">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="layout columns staticacc interactive"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px; display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<th class="device_width cell ssi_subhead" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:15px 30px 0px 0px; word-break:break-word;font-weight:normal;">
<!--[if mso]>
<p
style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:20px; text-align:left;color: #006EAD;margin:0">
<strong style="font-family: Arial,  Helvetica,  sans-serif;">Collapse</strong>
</p>
<![endif]-->
<!--[if !mso] -->
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:20px; text-align:left;color: #006EAD;margin:0">
<strong style="font-family: Arial,  Helvetica,  sans-serif;">Collapse</strong></p>
<!--[endif]-->
</th></tr></table></td></tr></table></label></td></tr>
<!--<![endif]-->
</tbody></table></td></table></div></div></td></tr></tbody></table></td></tr></tbody></table></div>
<!--[if mso | IE]>
</td>
</tr>
</table>
<![endif]-->
</td></tr></tbody></table></div>
<!--[if mso | IE]>
</td>
</tr>
</table>
<![endif]-->
</div>
<!-- Accordion Section ends -->
</td></tr></tbody></table></th></tr></tbody></table></th></tr></tbody></table></td></tr>
<!--[if !mso] --> 
<tr>
<td class="cell ssi_headline staticacc interactive" align="left" valign="top" style="display: none; border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
<tr><th class="spacer lnht15 layout columns" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[endif]-->
<tr>
<td class="cell ssi_headline fallback" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
<tr><th class="spacer layout columns lnht15" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<tr><th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 26px 0px 26px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;"><tbody>
<tr><td class="device_width cell ssi_headline" align="center" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:20px; text-align:center;color: #000000;margin:0">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000;font-style: italic;">Selected Safety Information continues below.</span></p></td></tr></tbody></table></th></tr>
<tr><td class="cell ssi_headline staticacc interactive" align="left" valign="top" style="display: none;border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
<tr><th class="spacer lnht15 layout columns" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;">&nbsp;</th></tr></table></td></tr>
<!--[if !mso] --> 
<tr>
<td class="cell ssi_headline fallback" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
<tr><th class="spacer layout columns lnht15" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table>
</td>
</tr>
<!--[endif]-->

<!-- 2nd-banner -->
<tr>
<th class="layout columns pdL20 pdR20 fallback" style="border-radius: 0px 0px 0px 0px;padding:0px 30px 0px 30px;background-color: #F1F1F1;">

<table width="100%" class="mobilebg2" cellspacing="0" cellpadding="0" border="0" style="background-image: url('https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png'); background-position:center center;background-repeat:no-repeat;background-size:100% 100%;">
<tr>
<th class="column__parent device_width" style="width: 600px;font-weight:normal;">
<!--[if gte mso 9]>
<v:rect xmlns:v="urn:schemas-microsoft-com:vml" fill="true" stroke="false" style="width:620px;height:75px;padding:0px 0px 0px 0px align:center;margin:0 auto;">
<v:fill type="frame" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png"/>
<v:textbox inset="0,0,0,0">
<![endif]-->
<table  width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><td style="padding:0px 0px 0px 0px" class="pdr21">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<th class="device_width cell subhead_large pd20" align="center" valign="middle" style="border-radius: 0px 0px 0px 0px; width:600px;padding:10px 50px 10px 50px; word-break:break-word; font-weight:normal;"><p class="fs18_lh24" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px; line-height:25px; text-align:center;color: #ffffff;margin:0">Read About Five Firsts for KEYTRUDA in the Treatment of Select Earlier-Stage Cancers</p></th></tr>
</table>
</td></tr></table>
<!--[if gte mso 9]>
</v:textbox>
</v:rect>
<![endif]-->
</th></tr></table></th></tr>
<tr><th class="spacer lnht20 layout columns fallback" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;background-color: #F1F1F1;">&nbsp;</th></tr>
<!-- Slide -->
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_headline pb0" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:500px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_headline pdlr20 pdT0" align="left" valign="top" style="padding:0px 30px 0px 30px;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;"><tbody>
<tr><td valign="top" align="center">
<!--[if !mso]><!-->
<form action="fooMain" style="margin-bottom: 0;">
<input class="yahoo" type="radio" name="actionmain" id="slide0" checked="checked" style="display: none!important; max-height: 0; visibility: hidden;">
<!--<![endif]-->
<table  border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<td valign="top" align="center">
<!--[if !mso]><!-->
<form action="foo">
<input class="yahoo" type="radio" checked="checked" name="action" id="slide-1" style="display: none!important; max-height: 0; visibility: hidden;">
<!--<![endif]-->
<table  border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<td valign="top" align="center">
<!--[if !mso]><!-->
<input class="yahoo" type="radio" name="action" id="slide-2" style="display: none!important; max-height: 0; visibility: hidden;">
<!--<![endif]-->
<table  border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<td valign="top" align="center">
<!--[if !mso]><!-->
<input class="yahoo" type="radio" name="action" id="slide-3" style="display: none!important; max-height: 0; visibility: hidden;">
<!--<![endif]-->
<table  border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<td valign="top" align="center">
<!--[if !mso]><!-->
<input class="yahoo" type="radio" name="action" id="slide-4" style="display: none!important; max-height: 0; visibility: hidden;">
<!--<![endif]-->
<table  border="0" cellpadding="0" cellspacing="0" class="" >
<tr>
<td valign="top" align="center">
<!--[if !mso]><!-->
<input class="yahoo" type="radio" name="action" id="slide-5" style="display: none!important; max-height: 0; visibility: hidden;">
<!--<![endif]-->
<table  border="0" cellpadding="0" cellspacing="0" class="" >
<tr>
<td valign="top" align="center">
<!--[if !mso]><!-->
<input class="yahoo" type="radio" name="action" id="slide-6" style="display: none!important; max-height: 0; visibility: hidden;">
<!--<![endif]-->
<table  border="0" cellpadding="0" cellspacing="0" class="" >
<tr>
<td valign="top" align="center">
<table border="0" cellpadding="0" cellspacing="0" class="" width="100%"><tr><td>
<table class="swoosh interactBorder" border="0" cellpadding="0" cellspacing="0" >
<tbody>

<!-- Breast-section -->
<tr>
    <td valign="top" align="center" class="slide1-content">
    <table border="0" cellpadding="0" cellspacing="0" class="" >
    
    <!--[if !mso] --> 
    <tr>
    
    <td valign="top" align="center" class="height_mob2 staticacc interactive" style="border-radius: 8px; display: none;">
    <table border="0" cellpadding="0" cellspacing="0" class="" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;">
    
    
    <tr>
    <td valign="top" align="center">
    <table valign="top" align="center" cellpadding="0" cellspacing="0">
    <tr>
    <th class="layout columns pd20 pdb0" style="border-radius: 8px 8px 8px 8px;padding:20px 20px 0px 20px;background-color: #ffffff;">
    
    <table width="100%" class="mobilebg2" cellspacing="0" cellpadding="0" border="0" style="background-image: url('https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png'); background-position:center center;background-repeat:no-repeat;background-size:100% 100%;">
    <tr>
    <th class="column__parent device_width"
    style="width: 558px;font-weight:normal;">
    <table width="558" class="mobilebg2 column__parent device_width" cellspacing="0" cellpadding="0" border="0" align="center" style="border-radius: 8px;background-repeat: no-repeat;">
    <!--[if gte mso 9]>
    <v:rect xmlns:v="urn:schemas-microsoft-com:vml" fill="true" stroke="false" style="width:558px;height:75px;padding:0px 0px 0px 0px align:center;margin:0 auto;">
    <v:fill type="frame" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png"/>
    <v:textbox inset="0,0,0,0">
    <![endif]-->
    
    <tr>
    <td style="padding:0px 0px 0px 0px" class="pdr21">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    
    <tr>
    <th class="device_width cell subhead_large pd20" align="center" valign="middle"
    style="border-radius: 0px 0px 0px 0px; width:600px;padding:10px 40px 10px 40px; word-break:break-word; font-weight:normal;">
    <p class="fs18_lh24" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px; line-height:25px; text-align:center;color: #ffffff;margin:0">Read About Five Firsts for KEYTRUDA in the Treatment of Select Earlier-Stage Cancers</p>
    </th>
    </tr>
    
    </table>
    </td>
    </tr>
    
    
    <!--[if gte mso 9]>
    </v:textbox>
    </v:rect>
    <![endif]-->
    </table>
    </th>
    </tr>
    </table>
    </th>
    </tr>
    </table>
    </td>
    </tr>
    
    <tr>
    <td valign="top" align="center" class="">
    <table border="0" cellpadding="0" cellspacing="0" class="" >
    <tr>
    <td valign="top" align="center" class="" style="border-radius: 8px; padding:20px 20px 0px 20px;">
    <table border="0" cellpadding="0" cellspacing="0" class="mobHeight mobHeightmedia" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE;height:306px;">
    <!--[if !mso] -->
    <tr><td class="spacer staticacc interactive lnht30" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
    <!--[endif]-->
    <tr>
    <td  align="left" class="pdT20 pdB20" valign="middle" style="padding:20px 20px 10px 20px;">
    <table border="0" cellpadding="0" cellspacing="0"class="" >
    <tr>
    <td class="column__width--40 column__height--100 cell image  isNested device_width" align="left" valign="middle" style="width:95px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <img class="desktop_img Brand " src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/breast.png" title="Breast icon" alt="Breast icon" width="70" style="display:block; max-width:100%;font-size: 6px !important;line-height: 6px !important;">
    </td>
    <td class="column__width--60 column__height--100 cell isNested device_width"
    align="left" valign="middle" height="0"
    style="width:421px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <td valign="middle" class="pdT25" align="left"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 18px;line-height: 22px;color: #2C6D3C; text-decoration: none !important;">
    KEYTRUDA is the first and only anti–PD-1 indicated as part of a complete regimen for high-risk early-stage triple-negative breast cancer (TNBC).
    </td>
    </tr>
    </table>
    </td>
    </tr>
    </table>
    </td>
    </tr>
    <!--[if !mso] -->
    <tr><td class="spacer staticacc interactive lnht10" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
    <!--[endif]-->
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0">
    KEYTRUDA is indicated for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
    </p>
    </td>
    </tr>
    <tr><th class="spacer" height="" style="height:25px;font-size:25px;line-height:25px;border:0px;padding:0px;">&nbsp;</th></tr>
    
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top"
    style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
    <table border="0" cellpadding="0" cellspacing="0" class="">
    <tr>
    <th class=" column__height--100 cell isNested wd32 disp_table" align="left" valign="middle" height="0"
    style="width:241px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <td valign="middle" align="left"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
    <a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=2492536"
    target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
    <span valign="middle"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-522 clinical data</span>
    
    </a>
    <a class="fallback" href="https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=2492536"
    target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
    <span valign="middle"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-522 clinical data</span>
    
    </a>
    </td>
    </tr>
    </table>
    </th>
    <th class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0"
    style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
    <a class="fallback" href="https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=2492536" target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
    <img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
    <a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=2492536" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
    <img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
    </td>
    </tr>
    </table>
    </th>
    </tr>
    </table>
    </td>
    </tr>
    
    <tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
    <!--[if !mso] -->
    <tr><td class="spacer staticacc interactive" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
    <tr><td class="spacer media420" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
    <!--[endif]-->
    
    </table>
    </td>
    </tr>
    </table>
    </td>
    </tr>
    
    
    </table>
    </td>
    
    </tr>
    <!--[endif]-->
    <tr>
    <td valign="top" align="center" class="height_mob2 fallback" style="border-radius: 8px; ">
    <table border="0" cellpadding="0" cellspacing="0" class="" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">
    
    <tr>
    <td align="left" class="pdT20 pdB20" valign="middle" style="padding:15px 20px 18px 20px;">
    <table border="0" cellpadding="0" cellspacing="0" class="">
    <tr>
    <td class="column__width--40 column__height--100 cell image  isNested device_width" align="left"
    valign="middle"
    style="width:95px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <img class="desktop_img Brand " src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/breast.png" title="Breast icon" alt="Breast icon" width="70" style="display:block; max-width:100%;font-size: 6px !important;line-height: 6px !important;">
    </td>
    <td class="column__width--60 column__height--100 cell isNested device_width" align="left"
    valign="middle" height="0"
    style="width:463px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <td valign="middle" class="pdT20" align="left"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 18px;line-height: 22px;color: #2C6D3C; text-decoration: none !important;">
    KEYTRUDA is the first and only anti–PD-1 indicated as part of a complete regimen for
    high-risk early-stage triple-negative breast cancer (TNBC).
    </td></tr></table></td></tr></table></td></tr>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
    #000000;margin:0">
    KEYTRUDA is indicated for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
    </p>
    </td>
    </tr>
    <tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top"
    style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
    <table border="0" cellpadding="0" cellspacing="0" class="">
    <tr>
    <th class=" column__height--100 cell isNested wd32 disp_table" align="left" valign="middle" height="0"
    style="width:245px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <td valign="middle" align="left"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
    <a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=2492536"
    target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
    <span valign="middle"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-522 clinical data</span>
    
    </a>
    <a class="fallback" href="https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=2492536"
    target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
    <span valign="middle"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-522 clinical data</span>
    </a></td></tr></table></th>
    <th class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0"
    style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
    <a class="fallback" href="https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=2492536" target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
    <img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
    <a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=2492536" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
    <img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
    </td></tr></table></th></tr></table></td></tr>
    <tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
    </table></td></tr>
    <!--[if !mso]><!-->
    <tr><th class="spacer lnht20 tap-arrows staticacc interactive" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;display: none;">&nbsp;</th></tr>
<tr><td class="tap-arrows staticacc interactive" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;line-height: 18px;color: #006EAD;text-align: center;display: none;"><strong>Tap arrows to see additional content.</strong></td></tr>
<tr><th class="spacer lnht11" height="" style="height:18px;font-size:18px;line-height:18px;border:0px;padding:0px;">&nbsp;</th></tr>
    <tr><td class="slide-bottom pd0" valign="top" align="center" style="display: none;">
    <table border="0" cellpadding="0" cellspacing="0" class="wid100 max-wid55" style="margin: auto;">
    <tr>
    <td width="50" height="50" class="mob_align" align="right" style="padding: 0 !important;">
    <label class="button1 slide5" for="slide-5" style="display: none; visibility: hidden; font-size:1px; line-height:1px;">
    <img class="imagewidth" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/left-arrow.png" title="Backward arrow" alt="Backward arrow" width="50" height="50" style="max-width:100%;font-size: 6px !important;line-height: 6px !important; color: #000000;">
    </label>
    </td>
    <td width="66" class="mob_width" align="center" >
    <span style="display: block;text-align: center;font-size: 18px;line-height: 30px; color: #006EAD;width:66px;"><strong>1 / 5</strong></span>
    </td>
    <td width="50" height="50" class="mob_align" align="left" style="padding: 0 !important;">
    <label class="button1 slide2" for="slide-2" style="display: none; visibility: hidden; font-size:1px; line-height:1px;">
    <img class="imagewidth" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/right-arrow.png" title="Forward arrow" alt="Forward arrow" width="50" height="50" style="max-width:100%;font-size: 6px !important;line-height: 6px !important; color: #000000;">
    </label></td></tr></table></td></tr>
    <!--<![endif]-->
    
    
    <!--[if !mso] --> 
    <tr>
    <td class="cell ssi_headline staticacc interactive" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;display: none;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr><th class="spacer lnht24 layout columns" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
    </table></td></tr>
    <!--[endif]-->
    <!--[if mso]>
    <tr>
    <td class="cell ssi_headline fallback" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr><th class="spacer layout columns lnht20" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
    </table></td></tr>
    <![endif]--> 
    </table></td></tr>


<!-- Static-SSI -->
<tr><td class="layout columns innerSSI fallback" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
    <tr><td class="layout columns pb20" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;background-color: #F1F1F1;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;"><tbody>
    <tr><th class="device_width cell ssi_headline pdlr0 pb0" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 20px 0px; word-break:break-word; font-weight:normal;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
    <tr><th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 8px 8px 8px 8px; padding:20px 24px 20px 24px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">
    <table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
    <tr><td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 15px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 22px; line-height:28px; text-align:left;color: #006EAD;margin:0">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #006EAD; font-weight: 500;">Selected Safety Information <em>(continued)</em></span>
    </p></td></tr>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000; text-decoration:underline;margin:0">Immune-Mediated Pneumonitis
    </p></td></tr>
    <tr>
    <td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
    <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;">
    <tbody>
    <tr>
    <td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
    •</td>
    <td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 3.4% (&zwj;94/2799&zwj;) of patients receiving KEYTRUDA, including fatal (0.1%), Grade 4 (0.3%), Grade 3 (&zwj;0.9%&zwj;), and Grade 2 (&zwj;1.3%&zwj;) reactions. Systemic corticosteroids were required in 67% (63/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3% (&zwj;36&zwj;) and withholding in 0.9% (&zwj;26&zwj;) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.
    </span></td></tr></tbody></table></th></tr></tbody></table></td></tr></tbody></table></th></tr>
    <tr>
    <th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
    <tbody>
    <tr>
    <td class="device_width cell ssi_headline" align="center" valign="top" style="border-radius: 0px 0px 0px 0px; padding:20px 0px 0px 0px; word-break:break-word; font-weight:normal"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:20px; text-align:center;color: #000000;margin:0">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000;font-style: italic;">Selected
    Safety Information continues below.</span>
    </p></td></tr></tbody></table></th></tr>
    </tbody></table></th></tr></tbody></table></td></tr></tbody></table></td></tr>
    <!-- Static-SSI ends-->





<!-- Melanoma-kinetic-section -->
<tr>
    <td valign="top" align="center" class="slide2-content">
    <table border="0" cellpadding="0" cellspacing="0" class="">
    <!--[if !mso] --> 
    <tr>
    
    <td valign="top" align="center" class="height_mob2 staticacc interactive" style="border-radius: 8px; display: none;">
    <table border="0" cellpadding="0" cellspacing="0" class="" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;">
    
    <tr>
    <td valign="top" align="center">
    <table valign="top" align="center" cellpadding="0" cellspacing="0">
    <tr>
    <th class="layout columns pd20 pdb0" style="border-radius: 8px 8px 8px 8px;padding:20px 20px 0px 20px;background-color: #ffffff;">
    
    <table width="100%" class="mobilebg2" cellspacing="0" cellpadding="0" border="0" style="background-image: url('https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png'); background-position:center center;background-repeat:no-repeat;background-size:100% 100%;">
    <tr>
    <th class="column__parent device_width"
    style="width: 558px;font-weight:normal;">
    <table width="558" class="mobilebg2 column__parent device_width" cellspacing="0" cellpadding="0" border="0" align="center" style="border-radius: 8px;background-repeat: no-repeat;">
    <!--[if gte mso 9]>
    <v:rect xmlns:v="urn:schemas-microsoft-com:vml" fill="true" stroke="false" style="width:558px;height:75px;padding:0px 0px 0px 0px align:center;margin:0 auto;">
    <v:fill type="frame" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png"/>
    <v:textbox inset="0,0,0,0">
    <![endif]-->
    
    <tr>
    <td style="padding:0px 0px 0px 0px" class="pdr21">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <th class="device_width cell subhead_large pd20" align="center" valign="middle" style="border-radius: 0px 0px 0px 0px; width:600px;padding:10px 40px 10px 40px; word-break:break-word; font-weight:normal;"><p class="fs18_lh24" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px; line-height:25px; text-align:center;color: #ffffff;margin:0">Read About Five Firsts for KEYTRUDA in the Treatment of Select Earlier-Stage Cancers</p></th></tr></table></td></tr>
    <!--[if gte mso 9]>
    </v:textbox>
    </v:rect>
    <![endif]-->
    </table>
    </th></tr></table></th></tr></table></td></tr>
    <tr>
    <td valign="top" align="center" class="">
    <table border="0" cellpadding="0" cellspacing="0" class="" >
    <tr>
    <td valign="top" align="center" class="" style="border-radius: 8px; padding:20px 20px 0px 20px;">
    <table border="0" cellpadding="0" cellspacing="0" class="mobHeight mobHeightmedia" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE;height: 306px;">
    <!--[if !mso] -->
    <tr><td class="spacer staticacc interactive lnht35" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
    <!--[endif]-->
    <tr>
    <td align="left" class="pdT20 pdB20" valign="middle" style="padding:11px 20px 0px 20px;">
    <table border="0" cellpadding="0" cellspacing="0" class="">
    <tr>
    <td class="column__width--40 column__height--100 cell image  isNested device_width" align="left"
    valign="middle"
    style="width:95px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <img class="desktop_img Brand"
    src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/melanoma.png"
    title="Epidermis icon" alt="Epidermis icon" width="70"
    style="display:block; max-width:100%;font-size: 6px !important;line-height: 6px !important;">
    </td>
    <td class="column__width--60 column__height--100 cell isNested device_width" align="left"
    valign="middle" height="0"
    style="width:421px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <td valign="middle" align="left" class="pdT28"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 18px;line-height: 22px;color: #2C6D3C; text-decoration: none !important;">
    KEYTRUDA is the first anti&zwj;–&zwj;PD-1 therapy FDA approved for&nbsp;the adjuvant treatment of patients (&zwj;12 years or older&zwj;) with completely resected stage IIB or IIC melanoma.<sup style="font-size: 60%;">1</sup>
    </td>
    </tr>
    </table>
    </td>
    </tr>
    </table>
    </td>
    </tr>
    <!--[if !mso] -->
    <tr><td class="spacer staticacc interactive lnht10" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
    <!--[endif]-->
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
    #000000;margin:0">
    KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (&zwj;12 years and older&zwj;) patients with stage IIB, IIC, or III melanoma following complete resection.
    </p>
    </td>
    </tr>
    <tr><th class="spacer" height="" style="height:25px;font-size:25px;line-height:25px;border:0px;padding:0px;">&nbsp;</th></tr>
    
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top"
    style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
    <table border="0" cellpadding="0" cellspacing="0" class="">
    <tr>
    <th class="column__height--100 cell isNested wid215 disp_table" align="left" valign="middle" height="0"
    style="width:389px; height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <td valign="middle" align="left"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
    <a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/melanoma-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=892667"
    target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
    <span valign="middle"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: 21px;text-decoration: none !important;">See KEYNOTE-716 and KEYNOTE-054 clinical data</span>
    </a>
    
    <a class="fallback" href="https://www.keytrudahcp.com/efficacy/melanoma-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=892667"
    target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
    <span valign="middle"
    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: 21px;text-decoration: none !important;">See KEYNOTE-716 and KEYNOTE-054 clinical data</span>
    </a>
    </td>
    </tr>
    </table>
    </th>
    <th class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0"
    style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" valign="middle">
    <tr>
    <td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
    <a class="fallback" href="https://www.keytrudahcp.com/efficacy/melanoma-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=892667" target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
    <img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
    <a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/melanoma-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=892667" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
    <img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
    </td>
    </tr>
    </table>
    </th>
    </tr>
    </table>
    </td>
    
    </tr>
    <tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
    <!--[if !mso] -->
    <tr><td class="spacer staticacc interactive" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
    <tr><td class="spacer media420" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
    <!--[endif]-->
    </table>
    </td>
    </tr>
    </table>
    </td>
    </tr>
    
    
    </table>
    </td>
    
    </tr>
    <!--[endif]-->
    <tr>
    <td valign="top" align="center" class="height_mob2 fallback" style="border-radius: 8px; ">
    <table border="0" cellpadding="0" cellspacing="0" class="" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">
    
    <tr>
    <td align="left" class="pdT20 pdB20" valign="middle" style="padding:15px 20px 18px 20px;">
    <table border="0" cellpadding="0" cellspacing="0" class="">
    <tr><td class="column__width--40 column__height--100 cell image  isNested device_width" align="left" valign="middle" style="width:95px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;"><img class="desktop_img Brand" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/melanoma.png" title="Epidermis icon" alt="Epidermis icon" width="70" style="display:block; max-width:100%;font-size: 6px !important;line-height: 6px !important;"></td>
    <td class="column__width--60 column__height--100 cell isNested device_width" align="left" valign="middle" height="0" style="width:463px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr><td valign="middle" align="left" class="pdT20" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px;line-height: 22px;color: #2C6D3C; text-decoration: none !important;">KEYTRUDA is the first anti&zwj;–&zwj;PD-1 therapy FDA approved for&nbsp;the adjuvant treatment of patients (&zwj;12 years or older&zwj;) with completely resected stage IIB or IIC melanoma.<span style="vertical-align: 9px;font-size: 11px;line-height: 0 !important;mso-line-height-alt:0px">1</span></td></tr></table></td></tr></table></td></tr>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0">KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (&zwj;12 years and older&zwj;) patients with stage IIB, IIC, or III melanoma following complete resection.</p></td>
    </tr>
    <tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
    
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
    <table border="0" cellpadding="0" cellspacing="0" class="">
    <tr>
    <th class="column__height--100 cell isNested wid215 disp_table" align="left" valign="middle" height="0" style="width:392px; height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <td valign="middle" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
    <a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/melanoma-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=892667" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
    <span valign="middle" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: 21px;text-decoration: none !important;">See KEYNOTE-716 and KEYNOTE-054 clinical data</span></a>
    
    <a class="fallback" href="https://www.keytrudahcp.com/efficacy/melanoma-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=892667" target="_blank" alias="Ask Merck" style="text-decoration: none !important;"><span valign="middle" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: 21px;text-decoration: none !important;">See KEYNOTE-716 and KEYNOTE-054 clinical data</span></a></td></tr></table></th>
    <th class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0" style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" valign="middle">
    <tr>
    <td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
    <a class="fallback" href="https://www.keytrudahcp.com/efficacy/melanoma-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=892667" target="_blank" alias="Ask Merck" style="text-decoration: none !important;"><img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
    <a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/melanoma-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=892667" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;"><img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
    </td>
    </tr></table></th></tr></table></td></tr>
    <tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
    </table></td></tr>
    
    
    <!--[if !mso]><!-->
    <tr><th class="spacer lnht20 tap-arrows staticacc interactive" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;display: none;">&nbsp;</th></tr>
<tr><td class="tap-arrows staticacc interactive" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;line-height: 18px;color: #006EAD;text-align: center;display: none;"><strong>Tap arrows to see additional content.</strong></td></tr>
<tr><th class="spacer lnht11" height="" style="height:18px;font-size:18px;line-height:18px;border:0px;padding:0px;">&nbsp;</th></tr>
    <tr>
    <td class="slide-bottom pd0" valign="top" align="center" style="display: none;">
    <table border="0" cellpadding="0" cellspacing="0" class="wid100 max-wid55" style="margin: auto;">
    <tr>
    <td width="50" height="50" class="mob_align" align="right" style="padding: 0 !important;">
    <label class="button1 slide1" for="slide-1" style="display: none; visibility: hidden; font-size:1px; line-height:1px;">
    <img class="imagewidth" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/left-arrow.png" title="Backward arrow" alt="Backward arrow" width="50" height="50" style="max-width:100%;font-size: 6px !important;line-height: 6px !important; color: #000000;">
    </label>
    </td>
    <td width="66" class="mob_width" align="center">
    <span style="display: block;text-align: center;font-size: 18px;line-height: 30px; color: #006EAD;width:66px;"><strong>2 / 5</strong></span>
    </td>
    <td width="50" height="50" class="mob_align" align="left" style="padding: 0 !important;">
    <label class="button1 slide3" for="slide-3" style="display: none; visibility: hidden; font-size:1px; line-height:1px;">
    <img class="imagewidth" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/right-arrow.png" title="Forward arrow" alt="Forward arrow" width="50" height="50" style="max-width:100%;font-size: 6px !important;line-height: 6px !important; color: #000000;">
    </label>
    </td>
    </tr>
    </table>
    </td>
    </tr>
    <!--<![endif]-->
    <!--[if !mso] --> 
    <tr>
    <td class="cell ssi_headline staticacc interactive" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;display: none;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <th class="spacer lnht24 layout columns" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th>
    </tr>
    </table>
    </td>
    </tr>
    <!--[endif]-->
    <!--[if mso]>
    <tr>
    <td class="cell ssi_headline fallback" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tr>
    <th class="spacer layout columns lnht20" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th>
    </tr>
    
    </table>
    </td>
    </tr>
    <![endif]--> 
    
    
    </table>
    </td>
    </tr>

<!-- Static-SSI -->
<tr>
    <td class="layout columns innerSSI fallback" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <td class="layout columns pb20" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;background-color: #F1F1F1;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
    <tbody>
    <tr>
    <th class="device_width cell ssi_headline pdlr0 pb0" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 20px 0px; word-break:break-word; font-weight:normal;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 8px 8px 8px 8px; padding:20px 24px 20px 24px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 15px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 22px; line-height:28px; text-align:left;color: #006EAD;margin:0">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #006EAD; font-weight: 500;">Selected Safety Information <em>(continued)</em></span>
    </p></td></tr>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000; text-decoration:underline;margin:0">Immune-Mediated Pneumonitis <em>(continued)</em></p></td></tr>
    <tr>
    <td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
    <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;">
    <tbody>
    <tr>
    <td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
    •</td>
    <td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">Pneumonitis occurred in 7% (41/580) of adult patients with resected non–small cell lung cancer (NSCLC) who received KEYTRUDA as a single agent for adjuvant treatment of NSCLC, including fatal (0.2%), Grade 4 (0.3%), and Grade 3 (1%) adverse reactions. Patients received high-dose corticosteroids for a median duration of 10 days (range: 1 day to 2.3 months). Pneumonitis led to discontinuation of KEYTRUDA in 26 (4.5%) of patients. Of the patients who developed pneumonitis, 54% interrupted KEYTRUDA, 63% discontinued KEYTRUDA, and 71% had resolution.
    </span></td></tr></tbody></table></th></tr></tbody></table></td></tr></tbody></table></th></tr>
    <tr>
    <th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;"><tbody>
    <tr>
    <td class="device_width cell ssi_headline" align="center" valign="top" style="border-radius: 0px 0px 0px 0px; padding:20px 0px 0px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:20px; text-align:center;color: #000000;margin:0">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000;font-style: italic;">Selected
    Safety Information continues below.</span>
    </p></td></tr></tbody></table></th></tr></tbody></table></th></tr></tbody></table></td></tr></tbody></table></td></tr>



<!-- Kidney-section -->
<tr>
<td valign="top" align="center" class="slide3-content" >
<table border="0" cellpadding="0" cellspacing="0" class="" >
<!--[if !mso] -->
<tr>
<td valign="top" align="center" class="height_mob2 staticacc interactive" style="border-radius: 8px; display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;">
<tr>
<td valign="top" align="center">
<table valign="top" align="center" cellpadding="0" cellspacing="0">
<tr><th class="layout columns pd20 pdb0" style="border-radius: 8px 8px 8px 8px;padding:20px 20px 0px 20px;background-color: #ffffff;">
<table width="100%" class="mobilebg2" cellspacing="0" cellpadding="0" border="0" style="background-image: url('https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png'); background-position:center center;background-repeat:no-repeat;background-size:100% 100%;">
<tr>
<th class="column__parent device_width" style="width: 558px;font-weight:normal;">
<table width="558" class="mobilebg2 column__parent device_width" cellspacing="0" cellpadding="0" border="0" align="center" style="border-radius: 8px;background-repeat: no-repeat;">
<!--[if gte mso 9]>
<v:rect xmlns:v="urn:schemas-microsoft-com:vml" fill="true" stroke="false" style="width:558px;height:75px;padding:0px 0px 0px 0px align:center;margin:0 auto;">
<v:fill type="frame" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png"/>
<v:textbox inset="0,0,0,0">
<![endif]-->
<tr>
<td style="padding:0px 0px 0px 0px" class="pdr21">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><th class="device_width cell subhead_large pd20" align="center" valign="middle" style="border-radius: 0px 0px 0px 0px; width:600px;padding:10px 40px 10px 40px; word-break:break-word; font-weight:normal;">
<p class="fs18_lh24" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px; line-height:25px; text-align:center;color: #ffffff;margin:0">Read About Five Firsts for KEYTRUDA in the Treatment of Select Earlier-Stage Cancers</p></th></tr></table></td></tr>
<!--[if gte mso 9]>
</v:textbox>
</v:rect>
<![endif]-->
</table></th></tr></table></th></tr></table></td></tr>
<tr>
<td valign="top" align="center" class="">
<table border="0" cellpadding="0" cellspacing="0" class="" >
<tr><td valign="top" align="center" class="" style="border-radius: 8px; padding:20px 20px 0px 20px;">
<table border="0" cellpadding="0" cellspacing="0" class="mobHeight mobHeightmedia" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE;height:306px;">
<!--[if !mso] -->
<tr><td class="spacer staticacc interactive lnht27" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
<!--[endif]-->
<tr>
<td align="left" valign="middle" style="padding:11px 20px 0px 20px;">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr><td class="column__width--40 column__height--100 cell image  isNested device_width" align="left" valign="middle" style="width:95px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;"><img class="desktop_img Brand" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/kidney.png" title="Kidney icon" alt="Kidney icon" width="70" style="display:block; max-width:100%;font-size: 6px !important;line-height: 6px !important;"></td>
<td class="column__width--60 column__height--100 cell isNested device_width" align="left" valign="middle" height="0" style="width:421px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><td valign="middle" class="pdT25" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px;line-height: 22px;color: #2C6D3C; text-decoration: none !important;mso-line-height-rule:exactly;">KEYTRUDA is the first and only immunotherapy approved for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence post nephrectomy.<span style="vertical-align: 7px;font-size: 12px;mso-line-height-rule:exactly;line-height: 0;">2</span>
</td></tr></table></td></tr></table></td></tr>
<!--[if !mso] -->
<tr><td class="spacer staticacc interactive lnht25" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
<!--[endif]-->
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0">
KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate&#00045;high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.</p></td>
</tr>
<tr><th class="spacer" height="" style="height:25px;font-size:25px;line-height:25px;border:0px;padding:0px;">&nbsp;</th></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<th class=" column__height--100 cell isNested wd32 disp_table" align="left" valign="middle" height="0" style="width:241px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><td valign="middle" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/adjuvant-renal-cell-carcinoma/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=1742483" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;"><span valign="middle" 
style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-564 clinical data</span>
</a>
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/adjuvant-renal-cell-carcinoma/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=1742483" target="_blank" alias="Ask Merck" style="text-decoration: none !important;"><span valign="middle" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-564 clinical data</span></a></td></tr></table></th>
<th class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0" style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/adjuvant-renal-cell-carcinoma/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=1742483" target="_blank" alias="Ask Merck" style="text-decoration: none !important;"><img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/adjuvant-renal-cell-carcinoma/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=1742483" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;"><img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
</td></tr></table></th></tr></table></td></tr>
<tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
<!--[if !mso] -->
<tr><td class="spacer staticacc interactive lnht22" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
<tr><td class="spacer media420" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
<!--[endif]-->
</table></td></tr></table></td></tr></table></td></tr>
<!--[endif]-->

<tr>
<td valign="top" align="center" class="height_mob2 fallback" style="border-radius: 8px; ">
<table border="0" cellpadding="0" cellspacing="0" class="" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">
<tr>
<td align="left" valign="middle" style="padding:15px 20px 18px 20px;">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<td class="column__width--40 column__height--100 cell image  isNested device_width" align="left"
valign="middle"
style="width:95px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<img class="desktop_img Brand" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/kidney.png" title="Kidney icon" alt="Kidney icon" width="70" style="display:block; max-width:100%;font-size: 6px !important;line-height: 6px !important;">
</td>
<td class="column__width--60 column__height--100 cell isNested device_width" align="left"
valign="middle" height="0"
style="width:463px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" class="pdT20" align="left"
style="font-family: Arial, Helvetica, sans-serif;font-size: 18px;line-height: 22px;color: #2C6D3C; text-decoration: none !important;">KEYTRUDA is the first and only immunotherapy approved for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence post nephrectomy.<span style="vertical-align: 7px;font-size: 12px;mso-line-height-rule:exactly;line-height: 0;">2</span>
</td></tr></table></td></tr></table></td></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0">
KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate&#00045;high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.</p></td></tr>
<tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<th class=" column__height--100 cell isNested wd32 disp_table" align="left" valign="middle" height="0" style="width:245px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><td valign="middle" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/adjuvant-renal-cell-carcinoma/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=1742483" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;"><span valign="middle" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-564 clinical data</span></a>
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/adjuvant-renal-cell-carcinoma/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=1742483" target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<span valign="middle" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-564 clinical data</span></a></td></tr></table></th>
<th class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0" style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/adjuvant-renal-cell-carcinoma/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=1742483" target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/adjuvant-renal-cell-carcinoma/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=1742483" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
</td></tr></table></th></tr></table></td></tr>
<tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[if !mso]><!-->
<!--[if !mso] --> 
<tr><th class="spacer lnht20 tap-arrows staticacc interactive" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;display: none;">&nbsp;</th></tr>
<tr><td class="tap-arrows staticacc interactive" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;line-height: 18px;color: #006EAD;text-align: center;display: none;"><strong>Tap arrows to see additional content.</strong></td></tr>
<tr><th class="spacer lnht11" height="" style="height:18px;font-size:18px;line-height:18px;border:0px;padding:0px;">&nbsp;</th></tr>
<!--[endif]-->
<tr>
<td class="slide-bottom pd0" valign="top" align="center" style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="wid100 max-wid55" style="margin: auto;">
<tr>
<td width="50" height="50" class="mob_align" align="right" style="padding: 0 !important;">
<label class="button1 slide2" for="slide-2" style="display: none; visibility: hidden; font-size:1px; line-height:1px;">
<img class="imagewidth" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/left-arrow.png" title="Backward arrow" alt="Backward arrow" width="50" height="50" style="max-width:100%;font-size: 6px !important;line-height: 6px !important; color: #000000;">
</label>
</td>
<td width="66" class="mob_width" align="center" >
<span style="display: block;text-align: center;font-size: 18px;line-height: 30px; color: #006EAD;width:66px;"><strong>3 / 5</strong></span>
</td>
<td width="50" height="50" class="mob_align" align="left" style="padding: 0 !important;">
<label class="button1 slide4" for="slide-4" style="display: none; visibility: hidden; font-size:1px; line-height:1px;">
<img class="imagewidth" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/right-arrow.png" title="Forward arrow" alt="Forward arrow" width="50" height="50" style="max-width:100%;font-size: 6px !important;line-height: 6px !important; color: #000000;">
</label></td></tr></table></td></tr>
<!--<![endif]-->


<!--[if !mso] --> 
<tr>
<td class="cell ssi_headline staticacc interactive" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><th class="spacer lnht24 layout columns" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[endif]-->
<!--[if mso]>
<tr><td class="cell ssi_headline fallback" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><th class="spacer layout columns lnht20" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<![endif]-->
</table></td></tr>

<tr>
    <td class="layout columns innerSSI fallback" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <td class="layout columns pb20" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;background-color: #F1F1F1;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
    <tbody>
    <tr>
    <th class="device_width cell ssi_headline pdlr0 pb0" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 20px 0px; word-break:break-word; font-weight:normal;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 8px 8px 8px 8px; padding:20px 24px 20px 24px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 20px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 22px; line-height:28px; text-align:left;color: #006EAD;margin:0">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #006EAD; font-weight: 500;">Selected Safety Information <em>(continued)</em></span>
    </p>
    </td>
    </tr>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000; text-decoration:underline;margin:0">Immune-Mediated Colitis
    </p>
    </td>
    </tr>
    
    <tr>
    <td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
    <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;">
    <tbody>
    <tr>
    <td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
    •</td>
    <td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 1.7% (&zwj;48/2799&zwj;) of patients receiving KEYTRUDA, including Grade 4 (&zwj;&#00060;0.1%&zwj;), Grade 3 (&zwj;1.1%&zwj;), and Grade 2 (&zwj;0.4%&zwj;) reactions. Systemic corticosteroids were required in 69% (&zwj;33/48&zwj;); additional immunosuppressant therapy was required in 4.2% of patients. Colitis led to permanent discontinuation of KEYTRUDA in 0.5% (&zwj;15&zwj;) and withholding in 0.5% (&zwj;13&zwj;) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Colitis resolved in 85% of the 48 patients.
    </span></td>
    </tr>
    </tbody>
    </table>
    </th>
    </tr>
    </tbody>
    </table>
    </td>
    </tr>
    </tbody>
    </table>
    </th>
    </tr>
    <tr>
    <th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
    <tbody>
    <tr>
    <td class="device_width cell ssi_headline" align="center" valign="top" style="border-radius: 0px 0px 0px 0px; padding:20px 0px 0px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:20px; text-align:center;color: #000000;margin:0">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000;font-style: italic;">Selected
    Safety Information continues below.</span>
    </p>
    </td>
    </tr>
    </tbody>
    </table>
    </th>
    </tr>
    
    </tbody>
    </table>
    </th>
    </tr>
    </tbody>
    </table>
    </td></tr></tbody></table></td></tr>



<!-- Bladder-section -->
<tr>
<td valign="top" align="center" class="slide4-content">
<table border="0" cellpadding="0" cellspacing="0" class="" >
<!--[if !mso] -->
<tr>
<td valign="top" align="center" class="height_mob2 staticacc interactive" style="border-radius: 8px; display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;">
<tr>
<td valign="top" align="center">
<table valign="top" align="center" cellpadding="0" cellspacing="0">
<tr>
<th class="layout columns pd20 pdb0" style="border-radius: 8px 8px 8px 8px;padding:20px 20px 0px 20px;background-color: #ffffff;">
<table width="100%" class="mobilebg2" cellspacing="0" cellpadding="0" border="0" style="background-image: url('https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png'); background-position:center center;background-repeat:no-repeat;background-size:100% 100%;">
<tr>
<th class="column__parent device_width" style="width: 558px;font-weight:normal;">
<table width="558" class="mobilebg2 column__parent device_width" cellspacing="0" cellpadding="0" border="0" align="center" style="border-radius: 8px;background-repeat: no-repeat;">
<!--[if gte mso 9]>
<v:rect xmlns:v="urn:schemas-microsoft-com:vml" fill="true" stroke="false" style="width:558px;height:75px;padding:0px 0px 0px 0px align:center;margin:0 auto;">
<v:fill type="frame" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png"/>
<v:textbox inset="0,0,0,0">
<![endif]-->

<tr>
<td style="padding:0px 0px 0px 0px" class="pdr21">
<table width="100%" cellspacing="0" cellpadding="0" border="0">

<tr>
<th class="device_width cell subhead_large pd20" align="center" valign="middle"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:10px 40px 10px 40px; word-break:break-word; font-weight:normal;">
<p class="fs18_lh24" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px; line-height:25px; text-align:center;color: #ffffff;margin:0">Read About Five Firsts for KEYTRUDA in the Treatment of Select Earlier-Stage Cancers</p></th></tr></table></td></tr>
<!--[if gte mso 9]>
</v:textbox>
</v:rect>
<![endif]-->
</table></th></tr></table></th></tr></table></td></tr>
<tr>
<td valign="top" align="center" class="">
<table border="0" cellpadding="0" cellspacing="0" class="" >
<tr><td valign="top" align="center" class="" style="border-radius: 8px; padding:20px 20px 0px 20px;">
<table border="0" cellpadding="0" cellspacing="0" class="mobHeight mobHeightmedia" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE;height:306px;">
<!--[if !mso] -->
<tr><td class="spacer staticacc interactive lnht25" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
<!--[endif]-->
<tr>
<td align="left" valign="middle" style="padding:10px 20px 2px 20px;">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<td class="column__width--40 column__height--100 cell image  isNested device_width" align="left" valign="middle" style="width:95px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;"><img class="desktop_img Brand" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/bladder.png" title="Bladder icon" alt="Bladder icon" width="70" style="display:block; max-width:100%;font-size: 6px !important;line-height: 6px !important;"></td>
<td class="column__width--60 column__height--100 cell isNested device_width" align="left" valign="middle" height="0" style="width:421px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" class="pdT22" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px;color: #2C6D3C; text-decoration: none !important;line-height: 22px;">KEYTRUDA is the first and only FDA-approved systemic treatment for certain patients with high-risk non-muscle invasive bladder cancer (&zwj;NMIBC&zwj;) who are Bacillus Calmette&zwj;-&zwj;Guerin (&zwj;BCG&zwj;)-unresponsive.
</td></tr></table></td>
</tr></table></td></tr>
<!--[if !mso] -->
<tr><td class="spacer staticacc interactive lnht22" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
<!--[endif]-->
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0">KEYTRUDA, as a single agent, is indicated for the treatment of patients with BCG-unresponsive, high&zwj;-&zwj;risk, NMIBC with carcinoma in situ (&zwj;CIS&zwj;) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
</p></td></tr>
<tr><th class="spacer" height="" style="height:25px;font-size:25px;line-height:25px;border:0px;padding:0px;">&nbsp;</th></tr>
<tr><td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<th class=" column__height--100 cell isNested wd32 disp_table" align="left" valign="middle" height="0"
style="width:241px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="left"
style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nmibc/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=2012650"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<span valign="middle"
style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-057 clinical data</span>
</a>
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/nmibc/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=2012650"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<span valign="middle"
style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-057 clinical data</span>
</a></td></tr></table></th>
<th class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0"
style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/nmibc/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=2012650" target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nmibc/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=2012650" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
</td></tr></table></th></tr></table></td></tr>
<tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
<!--[if !mso] -->
<tr><td class="spacer staticacc interactive lnht10" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
<tr><td class="spacer media420" height="" style="height:30px;font-size:30px;line-height:30px;border:0px;padding:0px;display: none;">&nbsp;</td></tr>
<!--[endif]-->
</table></td></tr></table></td></tr>
</table></td></tr>
<!--[endif]-->

<tr>
<td valign="top" align="center" class="height_mob2 fallback" style="border-radius: 8px; ">
<table border="0" cellpadding="0" cellspacing="0" class="" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">

<tr>
<td align="left" valign="middle" style="padding:15px 20px 18px 20px;">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<td class="column__width--40 column__height--100 cell image  isNested device_width" align="left"
valign="middle"
style="width:95px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<img class="desktop_img Brand" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/bladder.png" title="Bladder icon" alt="Bladder icon" width="70" style="display:block; max-width:100%;font-size: 6px !important;line-height: 6px !important;">
</td>
<td class="column__width--60 column__height--100 cell isNested device_width" align="left"
valign="middle" height="0"
style="width:463px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" class="pdT20" align="left"
style="font-family: Arial, Helvetica, sans-serif;font-size: 18px;color: #2C6D3C; text-decoration: none !important;line-height: 22px;">
KEYTRUDA is the first and only FDA-approved systemic treatment for certain patients with high-risk non-muscle invasive bladder cancer (&zwj;NMIBC&zwj;) who are Bacillus Calmette&zwj;-&zwj;Guerin (&zwj;BCG&zwj;)-unresponsive.
</td></tr></table></td></tr></table></td></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0">KEYTRUDA, as a single agent, is indicated for the treatment of patients with BCG-unresponsive, high&zwj;-&zwj;risk, NMIBC with carcinoma in situ (&zwj;CIS&zwj;) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.</p></td></tr>
<tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<th class=" column__height--100 cell isNested wd32 disp_table" align="left" valign="middle" height="0"
style="width:245px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nmibc/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=2012650" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<span valign="middle" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-057 clinical data</span></a>
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/nmibc/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=2012650"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<span valign="middle"
style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-057 clinical data</span>
</a></td></tr></table></th>
<th class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0" style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/nmibc/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=2012650" target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nmibc/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=2012650" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
</td></tr></table></th></tr></table></td></tr>
<tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[if !mso]><!-->
<tr><th class="spacer lnht20 tap-arrows staticacc interactive" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;display: none;">&nbsp;</th></tr>
<tr><td class="tap-arrows staticacc interactive" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;line-height: 18px;color: #006EAD;text-align: center;display: none;"><strong>Tap arrows to see additional content.</strong></td></tr>
<tr><th class="spacer lnht11" height="" style="height:18px;font-size:18px;line-height:18px;border:0px;padding:0px;">&nbsp;</th></tr>
<tr>
<td class="slide-bottom pd0" valign="top" align="center" style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="wid100 max-wid55" style="margin: auto;">
<tr>
<td width="50" height="50" class="mob_align" align="right" style="padding: 0 !important;">
<label class="button1 slide3" for="slide-3" style="display: none; visibility: hidden; font-size:1px; line-height:1px;">
<img class="imagewidth" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/left-arrow.png" title="Backward arrow" alt="Backward arrow" width="50" height="50" style="max-width:100%;font-size: 6px !important;line-height: 6px !important; color: #000000;">
</label>
</td>
<td width="66" class="mob_width" align="center">
<span style="display: block;text-align: center;font-size: 18px;line-height: 30px; color: #006EAD; width:66px;"><strong>4 / 5</strong></span>
</td>
<td width="50" height="50" class="mob_align" align="left" style="padding: 0 !important;">
<label class="button1 slide5" for="slide-5" style="display: none; visibility: hidden; font-size:1px; line-height:1px;">
<img class="imagewidth" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/right-arrow.png" title="Forward arrow" alt="Forward arrow" width="50" height="50" style="max-width:100%;font-size: 6px !important;line-height: 6px !important; color: #000000;">
</label></td></tr></table></td></tr>
<!--<![endif]-->


<!--[if !mso] --> 
<tr>
<td class="cell ssi_headline staticacc interactive" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><th class="spacer lnht24 layout columns" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[endif]-->
<!--[if mso]>
<tr>
<td class="cell ssi_headline fallback" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><th class="spacer layout columns lnht20" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<![endif]-->
</table></td></tr>

<tr><td class="layout columns innerSSI fallback" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <td class="layout columns pb20" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;background-color: #F1F1F1;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
    <tbody>
    <tr><th class="device_width cell ssi_headline pdlr0 pb0" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 20px 0px; word-break:break-word; font-weight:normal;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
    <tr>
    <th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 8px 8px 8px 8px; padding:20px 24px 20px 24px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">
    <table width="100%" cellspacing="0" cellpadding="0" border="0">
    <tbody>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 20px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 22px; line-height:28px; text-align:left;color: #006EAD;margin:0">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #006EAD; font-weight: 500;">Selected Safety Information <em>(continued)</em></span></p></td></tr>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 7px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000; text-decoration:underline;margin:0">
    Hepatotoxicity and Immune-Mediated Hepatitis</p></td></tr>
    <tr>
    <td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
    <p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0"><em>
    KEYTRUDA as a Single Agent</em></p></td></tr>
    <tr>
    <td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
    <tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
    <table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
    <tr>
    <td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
    <td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
    KEYTRUDA can
    cause
    immune-mediated
    hepatitis.
    Immune-mediated
    hepatitis
    occurred in 0.7%
    (19/2799) of
    patients
    receiving
    KEYTRUDA,
    including Grade
    4
    (&#00060;0.1%&zwj;),
    Grade 3&nbsp;(0.4%),
    and Grade 2
    (0.1%)
    reactions.
    Systemic
    corticosteroids
    were required in
    68% (13/19) of
    patients;
    additional
    immunosuppressant
    therapy was
    required in 11%
    of patients.
    Hepatitis led to
    permanent
    discontinuation
    of KEYTRUDA in
    0.2% (6) and
    withholding in
    0.3% (9) of
    patients. All
    patients who
    were withheld
    reinitiated
    KEYTRUDA after
    symptom
    improvement; of
    these, none had
    recurrence.
    Hepatitis
    resolved in 79%
    of the 19
    patients.</span>
    </td></tr></tbody></table></th></tr></tbody></table></td></tr></tbody></table></th></tr>
    <tr>
    <th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;"><tbody>
    <tr>
    <td class="device_width cell ssi_headline" align="center" valign="top" style="border-radius: 0px 0px 0px 0px; padding:20px 0px 0px 0px; word-break:break-word; font-weight:normal"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:20px; text-align:center;color: #000000;margin:0">
    <span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000;font-style: italic;">Selected
    Safety Information continues below.</span></p></td></tr></tbody></table></th></tr>
    </tbody></table></th></tr></tbody></table></td></tr></tbody></table></td></tr>




<!-- Lung-section -->
<tr>
<td valign="top" align="center" class="slide5-content">
<table border="0" cellpadding="0" cellspacing="0" class="" >
<!--[if !mso] -->
<tr>
<td valign="top" align="center" class="height_mob2 staticacc interactive" style="border-radius: 8px; display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;">

<tr>
<td valign="top" align="center">
<table valign="top" align="center" cellpadding="0" cellspacing="0">
<tr>
<th class="layout columns pd20 pdb0" style="border-radius: 8px 8px 8px 8px;padding:20px 20px 0px 20px;background-color: #ffffff;">
<table width="100%" class="mobilebg2" cellspacing="0" cellpadding="0" border="0" style="background-image: url('https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png'); background-position:center center;background-repeat:no-repeat;background-size:100% 100%;">
<tr>
<th class="column__parent device_width" style="width: 558px;font-weight:normal;">
<table width="558" class="mobilebg2 column__parent device_width" cellspacing="0" cellpadding="0" border="0" align="center" style="border-radius: 8px;background-repeat: no-repeat;">
<!--[if gte mso 9]>
<v:rect xmlns:v="urn:schemas-microsoft-com:vml" fill="true" stroke="false" style="width:558px;height:75px;padding:0px 0px 0px 0px align:center;margin:0 auto;">
<v:fill type="frame" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Desktop_Subhead_Background.png"/>
<v:textbox inset="0,0,0,0">
<![endif]-->

<tr>
<td style="padding:0px 0px 0px 0px" class="pdr21">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<th class="device_width cell subhead_large pd20" align="center" valign="middle"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:10px 40px 10px 40px; word-break:break-word; font-weight:normal;">
<p class="fs18_lh24" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px; line-height:25px; text-align:center;color: #ffffff;margin:0">Read About Five Firsts for KEYTRUDA in the Treatment of Select Earlier-Stage Cancers</p></th></tr></table></td></tr>
<!--[if gte mso 9]>
</v:textbox>
</v:rect>
<![endif]-->
</table></th></tr></table></th></tr></table></td></tr>
<tr>
<td valign="top" align="center" class="">
<table border="0" cellpadding="0" cellspacing="0" class="" >
<tr>
<td valign="top" align="center" class="" style="border-radius: 8px; padding:20px 20px 0px 20px;">
<table border="0" cellpadding="0" cellspacing="0" class="mobHeight mobHeightmedia" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE;height:306px;">
<tr>
<td align="left" class="pdT20 pdB20" valign="middle" style="padding:15px 20px 18px 20px;">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<td class="column__width--40 column__height--100 cell image  isNested device_width" align="left"
valign="middle"
style="width:95px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;"><img class="desktop_img Brand" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/lung.png" title="Lung icon" alt="Lung icon" width="70" style="display:block; max-width:100%;font-size: 6px !important;line-height: 6px !important;">
</td>
<td class="column__width--60 column__height--100 cell isNested device_width" align="left" valign="middle" height="0" style="width:421px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" class="pdT20" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px;line-height: 22px;color: #2C6D3C; text-decoration: none !important;">KEYTRUDA is the first IO with 2 approved indications for certain patients with earlier-stage non&zwj;—&zwj;small cell lung cancer (&zwj;NSCLC&zwj;).
</td></tr></table></td></tr></table></td></tr>

<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 10px 20px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0">
KEYTRUDA is indicated for the treatment of patients with resectable (&zwj;tumors &#8805;4 cm or node positive&zwj;) NSCLC in combination with platinum&#00045;containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.</p></td></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0">
KEYTRUDA, as a single agent, is indicated for adjuvant treatment following resection and platinum&#00045;based chemotherapy for adult patients with stage IB (&zwj;T2a&zwj;&nbsp;&zwj;&#8805;4&zwj;&nbsp;&zwj;cm&zwj;), II, or IIIA NSCLC.</p></td></tr>
<tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
<tr>
<td class="cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<table border="0" cellpadding="0" cellspacing="0" class="" width="">
<tr>
<td width="49%" class="cell ssi_headline column__width--100 responMobi" align="left" valign="middle" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
<table border="0" cellpadding="0" cellspacing="0" class="" valign="middle" width="">
<tr>
<td class="column__height--100 cell isNested disp_table" align="left" valign="middle" height="0" style="height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="" valign="middle" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nsclc-neoadjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=900620"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<span valign="middle"
style="font-family: Arial, Helvetica, sans-serif;font-size: 15px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-671 clinical data</span></a>
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/nsclc-neoadjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=900620"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<span valign="middle"
style="font-family: Arial, Helvetica, sans-serif;font-size: 15px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-671 clinical data</span></a></td></tr></table></td>
<td class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0" style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="" cellspacing="0" align="center" cellpadding="0" border="0" valign="middle">
<tr>
<td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/nsclc-neoadjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=900620" target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nsclc-neoadjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=900620" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
</td></tr></table></td></tr></table></td>
<td width="1%" class="height20 responMobi" valign="middle">&nbsp;</td>
<td width="49%" class="cell ssi_headline column__width--100 responMobi" align="left" valign="middle" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
<table border="0" cellpadding="0" cellspacing="0" class="" valign="middle" width="">
<tr>
<td class="column__height--100 cell isNested disp_table" align="left" valign="middle" height="0" style="height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="" valign="middle" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nsclc-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=900620"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<span valign="middle"
style="font-family: Arial, Helvetica, sans-serif;font-size: 15px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-091 clinical data</span></a>
<a class=fallback href="https://www.keytrudahcp.com/efficacy/nsclc-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=900620"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<span valign="middle" style="font-family: Arial, Helvetica, sans-serif;font-size: 15px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-091 clinical data</span></a></td></tr></table></td>
<td class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0" style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="" cellspacing="0" valign="middle" align="center" cellpadding="0" border="0">
<tr>
<td valign="middle" align="center" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/nsclc-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=900620" target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nsclc-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=900620" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
</td></tr></table></td></tr></table></td></tr></table></td></tr>
<tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr></table></td></tr></table></td></tr>
<!--[endif]-->

<tr>
<td valign="top" align="center" class="height_mob2 fallback" style="border-radius: 8px; ">
<table border="0" cellpadding="0" cellspacing="0" class="" style="border-radius: 8px 8px 8px 8px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">

<tr>
<td align="left" class="pdT20 pdB20" valign="middle" style="padding:15px 20px 18px 20px;">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<td class="column__width--40 column__height--100 cell image  isNested device_width" align="left" valign="middle" style="width:95px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;"><img class="desktop_img Brand" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/lung.png" title="Lung icon" alt="Lung icon" width="70" style="display:block; max-width:100%;font-size: 6px !important;line-height: 6px !important;">
</td>
<td class="column__width--60 column__height--100 cell isNested device_width" align="left" valign="middle" height="0" style="width:463px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" class="pdT20" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 18px;line-height: 22px;color: #2C6D3C; text-decoration: none !important;">KEYTRUDA is the first IO with 2 approved indications for certain patients with earlier-stage non—small cell lung cancer (&zwj;NSCLC&zwj;).
</td></tr></table></td></tr></table></td></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 10px 20px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0">
KEYTRUDA is indicated for the treatment of patients with resectable (tumors &#8805;4 cm or node positive)
NSCLC in combination with platinum&#00045;containing chemotherapy as neoadjuvant treatment, and then
continued as a single agent as adjuvant treatment after surgery.</p></td></tr>
<tr><td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0">
KEYTRUDA, as a single agent, is indicated for adjuvant treatment following resection and
platinum&#00045;based chemotherapy for adult patients with stage IB (T2a &#8805;4 cm), II, or IIIA NSCLC.</p></td>
</tr>
<tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
<tr><td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr><th class=" column__height--100 cell isNested wd32 disp_table" align="left" valign="middle" height="0" style="width:245px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
	
<!--[if !mso]><!-->
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nsclc-neoadjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=900620" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<span valign="middle" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-671 clinical data</span></a>
<!--<![endif]-->

<a class="fallback" href="https://www.keytrudahcp.com/efficacy/nsclc-neoadjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=900620"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<span valign="middle"
style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-671 clinical data</span></a></td></tr></table></th>
<th class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0" style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/nsclc-neoadjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=900620" target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nsclc-neoadjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=900620" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
</td></tr></table></th></tr></table></td>
</tr><tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 20px 0px 20px; word-break:break-word; font-weight:normal">
<table border="0" cellpadding="0" cellspacing="0" class="">
<tr>
<th class=" column__height--100 cell isNested wd32 disp_table" align="left" valign="middle" height="0"
style="width:245px;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="left"
style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nsclc-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=900620"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;">
<span valign="middle"
style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-091 clinical data</span>

</a>
<a class=fallback href="https://www.keytrudahcp.com/efficacy/nsclc-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=900620"
target="_blank" alias="Ask Merck" style="text-decoration: none !important;">
<span valign="middle"
style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important;">See KEYNOTE-091 clinical data</span>
</a></td></tr></table></th>
<th class=" column__height--100 cell isNested disp_table" align="left" valign="middle" height="0" style="width:30px !important;height:0px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td valign="middle" align="left" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD; text-decoration: none !important;">
<a class="fallback" href="https://www.keytrudahcp.com/efficacy/nsclc-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=static&UTM_ctaproductid=900620" target="_blank" alias="Ask Merck" style="text-decoration: none !important;"><img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
<a class="staticacc interactive" href="https://www.keytrudahcp.com/efficacy/nsclc-adjuvant-therapy/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%&UTM_click=kinetic&UTM_ctaproductid=900620" target="_blank" alias="Ask Merck" style="text-decoration: none !important;display: none;"><img class="" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png" title="Arrow icon" alt="Arrow icon" width="20" valign="middle" border="0" style="font-size: 5px !important;line-height: 5px !important;"></a>
</td></tr></table></th></tr></table></td>
</tr><tr><th class="spacer" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[if !mso]><!-->
<tr><th class="spacer lnht20 tap-arrows staticacc interactive" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;display: none;">&nbsp;</th></tr>
<tr><td class="tap-arrows staticacc interactive" style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;line-height: 18px;color: #006EAD;text-align: center;display: none;"><strong>Tap arrows to see additional content.</strong></td></tr>
<tr><th class="spacer lnht11" height="" style="height:18px;font-size:18px;line-height:18px;border:0px;padding:0px;">&nbsp;</th></tr>
<tr>
<td class="slide-bottom pd0" valign="top" align="center" style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="wid100 max-wid55" style="margin: auto;">
<tr>
<td width="50" height="50" class="mob_align" align="right" style="padding: 0 !important;">
<label class="button1 slide4" for="slide-4" style="display: none; visibility: hidden; font-size:1px; line-height:1px;">
<img class="imagewidth" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/left-arrow.png" title="Backward arrow" alt="Backward arrow" width="50" height="50" style="max-width:100%;font-size: 6px !important;line-height: 6px !important; color: #000000;">
</label></td>
<td width="66" class="mob_width" align="center">
<span style="display: block;text-align: center;font-size: 18px;line-height: 30px; color: #006EAD;width:66px;"><strong>5 / 5</strong></span>
</td>
<td width="50" height="50" class="mob_align" align="left" style="padding: 0 !important;">
<label class="button1 slide1" for="slide-1" style="display: none; visibility: hidden; font-size:1px; line-height:1px;">
<img class="imagewidth" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/right-arrow.png" title="Forward arrow" alt="Forward arrow" width="50" height="50" style="max-width:100%;font-size: 6px !important;line-height: 6px !important; color: #000000;">
</label></td></tr></table></td></tr>
<!--<![endif]-->


<!--[if !mso] --> 
<tr>
<td class="cell ssi_headline staticacc interactive" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><th class="spacer lnht24 layout columns" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
</table></td></tr>
<!--[endif]-->
<!--[if mso]>
<tr>
<td class="cell ssi_headline fallback" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><th class="spacer layout columns lnht20" height="" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th>
</tr></table></td></tr>
<![endif]--> 
</table></td></tr>

</tbody></table></td></tr></table></td></tr></table></td></tr></table></td></tr></table></td></tr></table></td></tr></table></td></tr></table>

<!--[if !mso]><!-->
</form>
<!--<![endif]-->
</td>
</tr>
</table>
<!--[if !mso]><!-->
</form>
<!--<![endif]-->
</td>
</tr>
</tbody></table></th></tr></tbody></table></th></tr></tbody></table></td></tr>

<!--[if !mso] --> 
<tr>
<td class="cell ssi_headline staticacc interactive" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;background-color: #F1F1F1;display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr><th class="spacer lnht15 layout columns" height="" style="height:28px;font-size:28px;line-height:28px;border:0px;padding:0px;">&nbsp;</th></tr></table></td></tr>
<!--[endif]-->


<!-- Bottom SSI-starts -->
<tr>
<td class="layout columns pdlr20" style="border-radius: 0px 0px 0px 0px;padding:0px 30px 0px 30px;background-color: #F1F1F1;">
<table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
<tbody>
<tr>
<th class="device_width cell ssi_headline pdlr0 pb0" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr>
<th class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 8px 8px 8px 8px; padding:20px 24px 24px 24px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">
<!--[if !mso]><!-->
<form action="fooMain2" style="margin-bottom: 0;">
<input class="yahoo" type="radio" name="actionmain2" id="slideSSI" checked="checked" style="display: none!important; max-height: 0; visibility: hidden;">
<!--<![endif]-->
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>


<tr>

<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 20px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 22px; line-height:28px; text-align:left;color: #006EAD;margin:0">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #006EAD; font-weight: 500;">Selected Safety Information <em class="outerCon">(continued)</em></span></p>
</td>

</tr>

<tr>
<!--[if !mso] --> 
<td class=" cell ssi_headline outerSSI staticacc interactive" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 5px 0px; word-break:break-word; font-weight:normal; display: none;">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0">
<strong>Severe and Fatal Immune-Mediated Adverse
Reactions</strong>
</p>
</td>
<!--[endif]-->
</tr>

<tr>
<!--[if !mso] --> 
<td class="layout columns outerSSI staticacc interactive" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 15px 0px; display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0" align="left" valign="top" width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left" valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">KEYTRUDA
is a monoclonal antibody that belongs to a class of drugs that bind to
either the programmed death receptor-1 (PD-1) or the programmed death ligand
1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of
the immune response, potentially breaking peripheral tolerance and inducing
immune-mediated adverse reactions. Immune-mediated adverse reactions, which
may be severe or fatal, can occur in any organ system or tissue, can affect
more than one body system simultaneously, and can occur at any time after
starting treatment or after discontinuation of treatment. Important
immune-mediated adverse reactions listed here may not include all possible
severe and fatal immune-mediated adverse reactions.</span>
</td>
</tr>
</tbody>
</table>
</th>

</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>

<tr>
<!--[if !mso] --> 
<td class="layout columns outerSSI staticacc interactive " style="border-radius: 0px 0px 0px 0px;padding:0px 0px 15px 0px; display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr>

<th class="device_width cell ssi_bullet" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0" align="left" valign="top" width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left" valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
Monitor patients closely for symptoms and signs that may be clinical
manifestations of underlying immune-mediated adverse reactions. Early
identification and management are essential to ensure safe use of
anti&zwj;&#08211;&zwj;PD&zwj;-&zwj;1&zwj;/&zwj;PD&zwj;-&zwj;L1 treatments.
Evaluate liver enzymes, creatinine, and thyroid function at baseline and
periodically during treatment. For patients with triple-negative breast
cancer (TNBC) treated with KEYTRUDA in the neoadjuvant setting, monitor
blood cortisol at baseline, prior to surgery, and as clinically indicated.
In cases of suspected immune-mediated adverse reactions, initiate
appropriate workup to exclude alternative etiologies, including infection.
Institute medical management promptly, including specialty consultation as
appropriate.</span>
</td>
</tr>
</tbody>
</table>
</th>

</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>

<tr>
<!--[if !mso] --> 
<td class="layout columns outerSSI staticacc  interactive " style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0" align="left" valign="top" width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left" valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
Withhold or
permanently
discontinue
KEYTRUDA
depending on
severity of the
immune-mediated
adverse
reaction. In
general, if
KEYTRUDA
requires
interruption or
discontinuation,
administer
systemic
corticosteroid
therapy (1 to 2&zwj;&nbsp;&zwj;mg/kg/day
prednisone or
equivalent)
until
improvement to
Grade 1 or less.
Upon improvement
to Grade 1 or
less, initiate
corticosteroid
taper and
continue to
taper over at
least 1 month.
Consider
administration
of other
systemic
immunosuppressants
in patients
whose adverse
reactions are
not controlled
with
corticosteroid
therapy.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>

<tr>
<!--[if !mso] --> 
<td class=" cell ssi_headline outerSSI staticacc interactive " align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal; display: none;">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000; text-decoration:underline;margin:0">
Immune-Mediated Pneumonitis
</p>
</td>
<!--[endif]-->
</tr>

<tr>
<!--[if !mso] --> 
<td class="layout columns outerSSI staticacc interactive " style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0" align="left" valign="top" width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left" valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
KEYTRUDA can
cause
immune-mediated
pneumonitis. The
incidence is
higher in
patients who
have received
prior thoracic
radiation.
Immune-mediated
pneumonitis
occurred in 3.4%
(94/2799) of
patients
receiving
KEYTRUDA,
including fatal
(0.1%), Grade 4
(0.3%), Grade 3
(0.9%), and
Grade 2 (1.3%)
reactions.
Systemic
corticosteroids
were required in
67% (63/94) of
patients.
Pneumonitis led
to permanent
discontinuation
of KEYTRUDA in
1.3% (36) and
withholding in
0.9% (26) of
patients. All
patients who
were withheld
reinitiated
KEYTRUDA after
symptom
improvement; of
these, 23% had
recurrence.
Pneumonitis
resolved in 59%
of the 94
patients.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>

<tr>
<!--[if !mso] --> 
<td class="layout columns outerSSI staticacc interactive" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0" align="left" valign="top" width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left" valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
Pneumonitis
occurred in 7%
(41/580) of
adult patients
with resected
non&#08211;small cell
lung cancer
(NSCLC) who
received
KEYTRUDA as a
single agent for
adjuvant
treatment of
NSCLC, including
fatal (0.2%),
Grade 4 (0.3%),
and Grade 3 (1%)
adverse
reactions.
Patients
received
high-dose
corticosteroids
for a median
duration of 10
days (range: 1
day to 2.3
months).
Pneumonitis led
to
discontinuation
of KEYTRUDA in
26 (4.5%) of
patients. Of the
patients who
developed
pneumonitis, 54%
interrupted
KEYTRUDA, 63%
discontinued
KEYTRUDA, and
71% had
resolution.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>

<tr>
<!--[if !mso] --> 
<td class=" cell ssi_headline outerSSI staticacc interactive " align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal; display: none;">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000; text-decoration:underline;margin:0;">
Immune-Mediated Colitis
</p>
</td>
<!--[endif]-->
</tr>

<tr>
<!--[if !mso] --> 
<td class="layout columns  outerSSI staticacc interactive " style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0" align="left" valign="top" width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left" valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
KEYTRUDA can
cause
immune-mediated
colitis, which
may present with
diarrhea.
Cytomegalovirus
infection/reactivation
has been
reported in
patients with
corticosteroid-refractory
immune-mediated
colitis. In
cases of
corticosteroid-refractory
colitis,
consider
repeating
infectious
workup to
exclude
alternative
etiologies.
Immune-mediated
colitis occurred
in 1.7%
(48/2799) of
patients
receiving
KEYTRUDA,
including Grade
4 (&#00060;0.1%&zwj;),
Grade 3 (1.1%),
and Grade 2&nbsp;(0.4%)
reactions.
Systemic
corticosteroids
were required in
69% (33/48);
additional
immunosuppressant
therapy was
required in 4.2%
of patients.
Colitis led to
permanent
discontinuation
of KEYTRUDA in
0.5% (15) and
withholding in
0.5% (13) of
patients. All
patients who
were withheld
reinitiated
KEYTRUDA after
symptom
improvement; of
these, 23% had
recurrence.
Colitis resolved
in 85% of the 48
patients.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>


<tr>
<!--[if !mso] --> 
<td class=" cell ssi_headline outerSSI staticacc interactive " align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 7px 0px; word-break:break-word; font-weight:normal;display: none;">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000; text-decoration:underline;margin:0;">
Hepatotoxicity and Immune-Mediated Hepatitis
</p>
</td>
<!--[endif]-->
</tr>

<tr>
<!--[if !mso] --> 
<td class=" cell ssi_headline outerSSI staticacc interactive " align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal;display: none;">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0;"><em>
KEYTRUDA as a Single Agent</em>
</p>
</td>
<!--[endif]-->
</tr>
<tr>
<!--[if !mso] --> 
<td class="layout columns outerSSI staticacc interactive " style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; display: none;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
KEYTRUDA can
cause
immune-mediated
hepatitis.
Immune-mediated
hepatitis
occurred in 0.7%
(19/2799) of
patients
receiving
KEYTRUDA,
including Grade
4
(&#00060;0.1%&zwj;),
Grade 3&nbsp;(0.4%),
and Grade 2
(0.1%)
reactions.
Systemic
corticosteroids
were required in
68% (13/19) of
patients;
additional
immunosuppressant
therapy was
required in 11%
of patients.
Hepatitis led to
permanent
discontinuation
of KEYTRUDA in
0.2% (6) and
withholding in
0.3% (9) of
patients. All
patients who
were withheld
reinitiated
KEYTRUDA after
symptom
improvement; of
these, none had
recurrence.
Hepatitis
resolved in 79%
of the 19
patients.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
<!--[endif]-->
</tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 7px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000; text-decoration:underline;margin:0;">
Immune-Mediated Endocrinopathies
</p>
</td>
</tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0;"><em>
Adrenal Insufficiency</em>
</p>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
KEYTRUDA can
cause primary or
secondary
adrenal
insufficiency.
For Grade 2 or
higher, initiate
symptomatic
treatment,
including
hormone
replacement as
clinically
indicated.
Withhold
KEYTRUDA
depending on
severity.
Adrenal
insufficiency
occurred in 0.8%
(22/2799) of
patients
receiving
KEYTRUDA,
including Grade
4
(&#00060;0.1%&zwj;),
Grade&nbsp;3&nbsp;(0.3%&zwj;)&zwj;,
and Grade 2
(0.3%)
reactions.
Systemic
corticosteroids
were required in
77% (17/22) of
patients; of
these, the
majority
remained on
systemic
corticosteroids.
Adrenal
insufficiency
led to permanent
discontinuation
of KEYTRUDA in
&#00060;0.1% (1)
and withholding
in 0.3% (8) of
patients. All
patients who
were withheld
reinitiated
KEYTRUDA after
symptom
improvement.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0;"><em>
Hypophysitis</em>
</p>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
KEYTRUDA can
cause
immune-mediated
hypophysitis.
Hypophysitis can
present with
acute symptoms
associated with
mass effect such
as headache,
photophobia, or
visual field
defects.
Hypophysitis can
cause
hypopituitarism.
Initiate hormone
replacement as
indicated.
Withhold or
permanently
discontinue
KEYTRUDA
depending on
severity.
Hypophysitis
occurred in 0.6%
(17/2799) of
patients
receiving
KEYTRUDA,
including Grade
4
(&#00060;0.1%),
Grade 3 (0.3%),
and Grade 2
(0.2%)
reactions.
Systemic
corticosteroids
were required in
94% (16/17) of
patients; of
these, the
majority
remained on
systemic
corticosteroids.
Hypophysitis led
to permanent
discontinuation
of KEYTRUDA in
0.1% (4) and
withholding in
0.3% (7) of
patients. All
patients who
were withheld
reinitiated
KEYTRUDA after
symptom
improvement.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0;"><em>
Thyroid Disorders</em>
</p>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
KEYTRUDA can
cause
immune-mediated
thyroid
disorders.
Thyroiditis can
present with or
without
endocrinopathy.
Hypothyroidism
can follow
hyperthyroidism.
Initiate hormone
replacement for
hypothyroidism
or institute
medical
management of
hyperthyroidism
as clinically
indicated.
Withhold or
permanently
discontinue
KEYTRUDA
depending on
severity.
Thyroiditis
occurred in 0.6%
(16/2799) of
patients
receiving
KEYTRUDA,
including Grade
2 (0.3%). None
discontinued,
but KEYTRUDA was
withheld in
&#00060;0.1% (1)
of patients.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
Hyperthyroidism
occurred in 3.4%
(96/2799) of
patients
receiving
KEYTRUDA,
including Grade
3 (0.1%) and
Grade 2 (0.8%).
It led to
permanent
discontinuation
of KEYTRUDA in
&#00060;0.1% (2)
and withholding
in 0.3% (7) of
patients. All
patients who
were withheld
reinitiated
KEYTRUDA after
symptom
improvement.
Hypothyroidism
occurred in 8%
(237/2799) of
patients
receiving
KEYTRUDA,
including Grade
3 (0.1%) and
Grade 2 (6.2%).
It led to
permanent
discontinuation
of KEYTRUDA in
&#00060;0.1% (1)
and withholding
in 0.5% (14) of
patients. All
patients who
were withheld
reinitiated
KEYTRUDA after
symptom
improvement. The
majority of
patients with
hypothyroidism
required
long-term
thyroid hormone
replacement. The
incidence of new
or worsening
hyperthyroidism
was higher in
580 patients
with resected
NSCLC, occurring
in 11% of
patients
receiving
KEYTRUDA as a
single agent as
adjuvant
treatment,
including Grade
3 (0.2%)
hyperthyroidism.
The incidence of
new or worsening
hypothyroidism
was higher in
580 patients
with resected
NSCLC, occurring
in 22% of
patients
receiving
KEYTRUDA as a
single agent as
adjuvant
treatment
(KEYNOTE-091),
including Grade
3 (0.3%)
hypothyroidism.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>

<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0;"><em>
Type 1 Diabetes Mellitus (DM), Which Can
Present With Diabetic Ketoacidosis</em>
</p>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
Monitor patients
for
hyperglycemia or
other signs and
symptoms of
diabetes.
Initiate
treatment with
insulin as
clinically
indicated.
Withhold
KEYTRUDA
depending on
severity. Type 1
DM occurred in
0.2% (6/2799) of
patients
receiving
KEYTRUDA. It led
to permanent
discontinuation
in &#00060;0.1%
(1) and
withholding of
KEYTRUDA in
&#00060;0.1% (1)
of patients. All
patients who
were withheld
reinitiated
KEYTRUDA after
symptom
improvement.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;text-decoration: underline;margin:0;">
Immune-Mediated Nephritis With Renal Dysfunction
</p>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
KEYTRUDA can
cause
immune-mediated
nephritis.
Immune-mediated
nephritis
occurred in 0.3%
(9/2799) of
patients
receiving
KEYTRUDA,
including Grade
4
(&#00060;0.1%),
Grade 3 (0.1%),
and Grade 2
(0.1%)
reactions.
Systemic
corticosteroids
were required in
89% (8/9) of
patients.
Nephritis led to
permanent
discontinuation
of KEYTRUDA in
0.1% (3) and
withholding in
0.1% (3) of
patients. All
patients who
were withheld
reinitiated
KEYTRUDA after
symptom
improvement; of
these, none had
recurrence.
Nephritis
resolved in 56%
of the 9
patients.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;text-decoration: underline;margin:0;">
Immune-Mediated Dermatologic Adverse Reactions
</p>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
KEYTRUDA can
cause
immune-mediated
rash or
dermatitis.
Exfoliative
dermatitis,
including
Stevens-Johnson
syndrome, drug
rash with
eosinophilia and
systemic
symptoms, and
toxic epidermal
necrolysis, has
occurred with
anti&#08211;PD&zwj;-&zwj;1/&zwj;PD&zwj;-&zwj;L1
treatments.
Topical
emollients
and/or topical
corticosteroids
may be adequate
to treat mild to
moderate
nonexfoliative
rashes. Withhold
or permanently
discontinue
KEYTRUDA
depending on
severity.
Immune-mediated
dermatologic
adverse
reactions
occurred in 1.4%
(38/2799) of
patients
receiving
KEYTRUDA,
including Grade
3 (1%) and Grade
2 (0.1%)
reactions.
Systemic
corticosteroids
were required in
40% (15/38) of
patients. These
reactions led to
permanent
discontinuation
in 0.1% (2) and
withholding of
KEYTRUDA in 0.6%
(16) of
patients. All
patients who
were withheld
reinitiated
KEYTRUDA after
symptom
improvement; of
these, 6% had
recurrence. The
reactions
resolved in 79%
of the 38
patients.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;text-decoration: underline;margin:0;">
Other Immune-Mediated Adverse Reactions
</p>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
The following
clinically
significant
immune-mediated
adverse
reactions
occurred at an
incidence of
&#00060;1%
(unless
otherwise noted)
in patients who
received
KEYTRUDA or were
reported with
the use of other
anti&#08211;PD&zwj;-&zwj;1/&zwj;PD&zwj;-&zwj;L1
treatments.
Severe or fatal
cases have been
reported for
some of these
adverse
reactions.
<em>Cardiac/Vascular:</em>
Myocarditis,
pericarditis,
vasculitis;
<em>Nervous
System:</em>
Meningitis,
encephalitis,
myelitis and
demyelination,
myasthenic
syndrome/myasthenia
gravis
(including
exacerbation),
Guillain-Barré
syndrome, nerve
paresis,
autoimmune
neuropathy;
<em>Ocular:</em>
Uveitis, iritis
and other ocular
inflammatory
toxicities can
occur. Some
cases can be
associated with
retinal
detachment.
Various grades
of visual
impairment,
including
blindness, can
occur. If
uveitis occurs
in combination
with other
immune-mediated
adverse
reactions,
consider a
Vogt-Koyanagi-Harada-like
syndrome, as
this may require
treatment with
systemic
steroids to
reduce the risk
of permanent
vision loss;<em>
Gastrointestinal:
</em>Pancreatitis,
to include
increases in
serum amylase
and lipase
levels,
gastritis,
duodenitis;
<em>Musculoskeletal
and
Connective
Tissue:</em>
Myositis/polymyositis,
rhabdomyolysis
(and associated
sequelae,
including renal
failure),
arthritis
(1.5%),
polymyalgia
rheumatica;
<em>Endocrine:</em>
Hypoparathyroidism;
<em>Hematologic/Immune:</em>
Hemolytic
anemia, aplastic
anemia,
hemophagocytic
lymphohistiocytosis,
systemic
inflammatory
response
syndrome,
histiocytic
necrotizing
lymphadenitis
(Kikuchi
lymphadenitis),
sarcoidosis,
immune
thrombocytopenic
purpura, solid
organ transplant
rejection, other
transplant
(including
corneal graft)
rejection.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0;"><strong>
Infusion-Related Reactions</strong>
</p>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
KEYTRUDA can
cause severe or
life-threatening
infusion-related
reactions,
including
hypersensitivity
and anaphylaxis,
which have been
reported in 0.2%
of 2799 patients
receiving
KEYTRUDA.
Monitor for
signs and
symptoms of
infusion-related
reactions.
Interrupt or
slow the rate of
infusion for
Grade 1 or Grade
2 reactions. For
Grade 3 or Grade
4 reactions,
stop infusion
and permanently
discontinue
KEYTRUDA.</span> </td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0;"><strong>
Complications of Allogeneic Hematopoietic
Stem Cell Transplantation (HSCT)</strong>
</p>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
Fatal and other
serious
complications
can occur in
patients who
receive
allogeneic HSCT
before or after
anti&#08211;PD&zwj;-&zwj;1/&zwj;PD&zwj;-&zwj;L1
treatments.
Transplant-related
complications
include
hyperacute
graft-versus-host
disease (GVHD),
acute and
chronic GVHD,
hepatic
veno-occlusive
disease after
reduced
intensity
conditioning,
and
steroid-requiring
febrile syndrome
(without an
identified
infectious
cause). These
complications
may occur
despite
intervening
therapy between
anti&#08211;PD&zwj;-&zwj;1/&zwj;PD&zwj;-&zwj;L1
treatments and
allogeneic HSCT.
Follow patients
closely for
evidence of
these
complications
and intervene
promptly.
Consider the
benefit vs risks
of using
anti&#08211;PD&zwj;-&zwj;1/&zwj;PD&zwj;-&zwj;L1
treatments prior
to or after an
allogeneic HSCT.</span>
</td>
</tr>
</tbody>
</table>
</th>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: 
#000000;margin:0;"><strong>
Increased Mortality in Patients With
Multiple Myeloma</strong>
</p>
</td>
</tr>
<tr>
<td class="layout columns"
style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0"
border="0">
<tbody>
<tr>
<th class="device_width cell ssi_bullet"
align="left" valign="top"
style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0"
cellspacing="0" border="0"
style="border: 0px;">
<tbody>
<tr>
<td class="list_item_0"
align="left"
valign="top"
width="15"
style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">
&#08226;</td>
<td align="left"
valign="top"
style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span
style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
In trials in
patients with
multiple
myeloma, the
addition of
KEYTRUDA to a
thalidomide
analogue plus
dexamethasone
resulted in
increased
mortality.
Treatment of
these patients
with an
anti&#08211;PD&zwj;-&zwj;1/&zwj;PD&zwj;-&zwj;L1
treatment in
this combination
is not
recommended
outside of
controlled
trials.</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0;"><strong>Embryofetal Toxicity</strong>
</p>
</td>
</tr>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
Based on its
mechanism of
action, KEYTRUDA
can cause fetal
harm when
administered to
a pregnant
woman. Advise
women of this
potential risk.
In females of
reproductive
potential,
verify pregnancy
status prior to
initiating
KEYTRUDA and
advise them to
use effective
contraception
during treatment
and for 4 months
after the last
dose.</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr><td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0;"><strong>Adverse Reactions</strong></p></td></tr>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 10px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">In KEYNOTE-054, when KEYTRUDA was administered as a single agent to patients with stage III melanoma, KEYTRUDA was permanently discontinued due to adverse reactions in 14% of 509 patients; the most common (≥1%) were pneumonitis (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred in 25% of patients receiving KEYTRUDA. The most common adverse reaction (≥20%) with KEYTRUDA was diarrhea (28%). In KEYNOTE-716, when KEYTRUDA was administered as a single agent to patients with stage IIB or IIC melanoma, adverse reactions occurring in patients with stage IIB or IIC melanoma were similar to those occurring in 1011 patients with stage III melanoma from KEYNOTE-054.</span></td></tr></tbody></table></th></tr>
<tr>
<th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">In KEYNOTE-671, adverse reactions occurring in patients with resectable
NSCLC receiving KEYTRUDA in combination with platinum-containing
chemotherapy, given as neoadjuvant treatment and continued as single-agent
adjuvant treatment, were generally similar to those occurring in patients in
other clinical trials across tumor types receiving KEYTRUDA in combination
with chemotherapy.</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">The most common adverse reactions (reported in &#8805;20%) in patients receiving KEYTRUDA in combination with chemotherapy were fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, weight loss, abdominal pain, arthralgia, myalgia, insomnia, palmar-plantar erythrodysesthesia, urinary tract infection, and hypothyroidism.</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">In the neoadjuvant phase of KEYNOTE-671, when KEYTRUDA was administered in combination with platinum-containing chemotherapy as neoadjuvant treatment, serious adverse reactions occurred in 34% of 396 patients. The most frequent (&#8805;2%) serious adverse reactions were pneumonia (4.8%), venous thromboembolism (3.3%), and anemia (2%). Fatal adverse reactions occurred in 1.3% of patients, including death due to unknown cause (0.8%), sepsis (0.3%), and immune-mediated lung disease (0.3%). Permanent discontinuation of any study drug due to an adverse reaction occurred in 18% of patients who received KEYTRUDA in combination with platinum-containing chemotherapy; the most frequent adverse reactions (&#8805;1%) that led to permanent discontinuation of any study drug were acute kidney injury (1.8%), interstitial lung disease (1.8%), anemia (1.5%), neutropenia (1.5%), and pneumonia (1.3%).</span></td></tr></tbody></table></th></tr>
</tbody></table></td></tr>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">Of the KEYTRUDA-treated patients who received neoadjuvant treatment, 6% of 396 patients did not receive surgery due to adverse reactions. The most frequent (&#8805;1%) adverse reaction that led to cancellation of surgery in the KEYTRUDA arm was interstitial lung disease (1%).</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">In the adjuvant phase of KEYNOTE-671, when KEYTRUDA was administered as a single agent as adjuvant treatment, serious adverse reactions occurred in 14% of 290 patients. The most frequent serious adverse reaction was pneumonia (3.4%). One fatal adverse reaction of pulmonary hemorrhage occurred. Permanent discontinuation of KEYTRUDA due to an adverse reaction occurred in 12% of patients who received KEYTRUDA as a single agent, given as adjuvant treatment; the most frequent adverse reactions (&#8805;1%) that led to permanent discontinuation of KEYTRUDA were diarrhea (1.7%), interstitial lung disease (1.4%), increased aspartate aminotransferase (AST) (1%), and musculoskeletal pain&nbsp;(1%&zwj;)&zwj;.</span></td></tr></tbody></table></th></tr></tbody></table></td></tr><tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">The most common adverse reactions for KEYTRUDA as a single agent (reported in &#8805;20% of patients) were fatigue, musculoskeletal pain, rash, diarrhea, pyrexia, cough, decreased appetite, pruritus, dyspnea, constipation, pain, abdominal pain, nausea, and hypothyroidism.</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>

<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">Adverse reactions observed in KEYNOTE-091 were generally similar to those occurring in other patients with NSCLC receiving KEYTRUDA as a single agent, with the exception of hypothyroidism (22%), hyperthyroidism (11%), and pneumonitis (7%). Two fatal adverse reactions of myocarditis occurred.</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr>
<td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">In KEYNOTE-057, KEYTRUDA was discontinued due to adverse reactions in 11% of 148 patients with high-risk non-muscle invasive bladder cancer (NMIBC). The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (1.4%). Serious adverse reactions occurred in 28% of patients; those &#8805;2% were pneumonia (3%), cardiac ischemia (2%), colitis (2%), pulmonary embolism (2%), sepsis (2%), and urinary tract infection (2%). The most common adverse reactions (&#8805;20%) were fatigue&nbsp;(29%&zwj;)&zwj;, diarrhea (24%), and rash (24%).</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">In KEYNOTE-564, when KEYTRUDA was administered as a single agent for the adjuvant treatment of renal cell carcinoma, serious adverse reactions occurred in 20% of patients receiving KEYTRUDA; the serious adverse reactions (&#8805;1%) were acute kidney injury, adrenal insufficiency, pneumonia, colitis, and diabetic ketoacidosis (1% each). Fatal adverse reactions occurred in 0.2% including 1 case of pneumonia. Discontinuation of KEYTRUDA due to adverse reactions occurred in 21% of 488 patients; the most common (&#8805;1%) were increased alanine aminotransferase (ALT) (1.6%), colitis (1%), and adrenal insufficiency (1%). The most common adverse reactions (&#8805;20%) were musculoskeletal pain (41%), fatigue (40%), rash (30%), diarrhea (27%), pruritus (23%), and hypothyroidism&nbsp;(21%&zwj;)&zwj;.</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody><tr>
<th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
In KEYNOTE-522, when KEYTRUDA was administered with neoadjuvant chemotherapy (carboplatin and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide) followed by surgery and continued adjuvant treatment with KEYTRUDA as a single agent (n=778) to patients with newly diagnosed, previously untreated, high-risk early-stage TNBC, fatal adverse reactions occurred in 0.9% of patients, including 1 each of adrenal crisis, autoimmune encephalitis, hepatitis, pneumonia, pneumonitis, pulmonary embolism, and sepsis in association with multiple organ dysfunction syndrome and myocardial infarction. Serious adverse reactions occurred in 44% of patients receiving KEYTRUDA; those ≥2% were febrile neutropenia (15%), pyrexia (3.7%), anemia (2.6%), and neutropenia&nbsp;(2.2%&zwj;)&zwj;. KEYTRUDA was discontinued in 20% of patients due to adverse reactions. The most common reactions (≥1%) resulting in permanent discontinuation were increased alanine aminotransferase (ALT) (2.7%), increased aspartate aminotransferase (AST) (1.5%), and rash (1%). The most common adverse reactions (≥20%) in patients receiving KEYTRUDA were fatigue (70%), nausea (67%), alopecia (61%), rash (52%), constipation (42%), diarrhea and peripheral neuropathy (41% each), stomatitis (34%), vomiting (31%), headache (30%), arthralgia (29%), pyrexia (28%), cough (26%), abdominal pain (24%), decreased appetite (23%), insomnia (21%), and myalgia (20%).
</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 7px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0;"><strong>Lactation</strong></p></td></tr>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
Because of the
potential for
serious adverse
reactions in
breastfed
children, advise
women not to
breastfeed
during treatment
and for 4 months
after the last
dose.</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr>
<td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 7px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0;"><strong>Pediatric Use</strong></p></td>
</tr>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 20px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody>
<tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px;">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;padding-bottom: 8px;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000;">
In KEYNOTE-051, 173 pediatric patients (65 pediatric patients aged 6 months
to younger than 12 years and 108 pediatric patients aged 12 years to 17
years) were administered KEYTRUDA 2 mg/kg every 3 weeks. The median duration
of exposure was 2.1 months (range: 1 day to 25 months).</span></td></tr><tr>
<td class="list_item_0" align="left" valign="top" width="15"style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:19px; mso-line-height-alt:19px">&#08226;</td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">
Adverse reactions that occurred at a ≥10% higher rate in pediatric patients
when compared to adults were pyrexia (33%), leukopenia (30%), vomiting
(29%), neutropenia (28%), headache (25%), abdominal pain (23%),
thrombocytopenia (22%), Grade 3 anemia&nbsp;(17%&zwj;)&zwj;, decreased lymphocyte count
(13%), and decreased white blood cell count (11%).</span>
</td></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr>
<td class="device_width cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
<p class="pdright" style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:20px; text-align:left;color: #006EAD;margin:0;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #262626; font-weight: 700;">Before
prescribing KEYTRUDA<span style="font-size: 10px; line-height: 4px; vertical-align: 4px;">&#00174;</span>&zwj;&nbsp;&zwj;(&zwj;pembrolizumab&zwj;), please read the accompanying&nbsp;<a href="https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf?UTM_term=BottomPI" target="_blank" alias="Prescribing Information" style="color: #006EAD; font-weight: 700;"><u>Prescribing Information</u></a>. The <a href="https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf" target="_blank" alias="Medication Guide" style="color: #006EAD; font-weight: 700;"><u>Medication Guide</u></a> also is available.</span></p></td></tr>
<tr><th class="device_width spacer" height="20" style="height:20px;font-size:20px;line-height:20px;border:0px;padding:0px;">&nbsp;</th></tr>
<tr><td class=" cell ssi_headline" align="left" valign="top" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 10px 0px; word-break:break-word; font-weight:normal">
<p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:18px; text-align:left;color: #000000;margin:0;"><strong>References</strong></p></td></tr>

<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 7px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody><tr><td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; mso-line-height-alt:19px">
1. </td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">Opdivo [&zwj;package insert&zwj;]. Bristol&zwj;-&zwj;Myers Squibb Company; 2&zwj;0&zwj;2&zwj;4.</span>
</td></tr></tbody></table></th></tr>
<tr>
<th class="device_width cell ssi_bullet" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 6px; word-break:break-word; font-weight:normal;">
<table width="100%" cellpadding="0" cellspacing="0" border="0" style="border: 0px;"><tbody><tr>
<td class="list_item_0" align="left" valign="top" width="15" style="width:17px; color:#000; font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; mso-line-height-alt:19px">
2. </td>
<td align="left" valign="top" style="mso-line-height-rule:exactly;line-height:18px;font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#000000;">
<span style="font-family: Arial,  Helvetica,  sans-serif;color: #000000">Choueiri TK, Tomczak P, Park SH, et al&zwj;; for the KEYNOTE&zwj;-&zwj;564 investigators. Adjuvant pembrolizumab after nephrectomy in renal&zwj;-&zwj;cell carcinoma. <em>N Engl J Med.</em> 2021;385(&zwj;8&zwj;):683&zwj;-&zwj;694.</span></td></tr></tbody></table></th></tr></tbody></table></td></tr>
</tbody></table></form></th></tr></tbody></table></th></tr></tbody></table></td></tr>

<tr>
    <td class="layout columns pdlr20 pdT15 pdB15" style="border-radius: 0px 0px 0px 0px;padding:30px 30px 30px 30px;background-color: #F1F1F1; border-bottom: 1px solid #BEBEBE;">
        <table width="100%" cellspacing="0" cellpadding="0" border="0" style="background-color: #F1F1F1;">
            <tbody>
                <tr>
                    <th class="device_width cell ssi_headline" align="left" valign="top"
                        style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;">
                        <table width="100%" cellspacing="0" cellpadding="0" border="0">
                            <tbody>
                                <tr>
                                    <th class="device_width cell ssi_headline pdlr20" align="left" valign="top" style="border-radius: 8px 8px 8px 8px; padding:40px 40px 0px 40px; word-break:break-word; font-weight:normal;background-color: #ffffff;border: 1px solid #BEBEBE; ">
                                        <table width="100%" cellspacing="0" cellpadding="0" border="0">
                                            <tbody>
                                                <tr>
                                                    <th class="device_width cell subhead" align="center" valign="top"
                                                        style="border-radius: 0px 0px 0px 0px; width:5400px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;">
                                                        <img class="desktop_img"
                                                            src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/contact-us.png"
                                                            title="Image" alt="Ask merck icon" width="60" height="60"
                                                            border="0"
                                                            style="display:block;height: 60px; max-width:100%;font-size: 6px !important;line-height: 6px !important;">
                                                    </th>
                                                </tr>
                                                <tr>
                                                    <td class=" cell ssi_headline" align="left" valign="top"
                                                        style="border-radius: 0px 0px 0px 0px; padding:20px 0px 20px 0px; word-break:break-word; font-weight:normal">
                                                        <p
                                                            style="font-family: Arial, Helvetica, sans-serif;font-size: 34px; line-height:52px; text-align:center;color: #000000;margin:0;">
                                                            <span
                                                                style="font-family: Arial,  Helvetica,  sans-serif;color: #000000;">Contact
                                                                Us</span></p>
                                                    </td>
                                                </tr>
                                                <tr>
                                                    <td class="cell ssi_headline" align="left" valign="top"
                                                        style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
                                                        <table width="100%" cellspacing="0" cellpadding="0" border="0">
                                                            <tr>
                                                                <td class="layout columns"
                                                                    style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
                                                                    <p class=""
                                                                        style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:21px; text-align:center;color: #000000;margin:0;">
                                                                        <span class=""
                                                                            style="font-family: Arial,  Helvetica,  sans-serif;color: #000000;">Ready
                                                                            to start a conversation about KEYTRUDA?
                                                                            Contact Merck today!</span></p>
                                                                </td>
                                                            </tr>
                                                        </table>
                                                    </td>
                                                </tr>
                                                <tr>
                                                    <th class="device_width spacer" height="40"
                                                        style="height:40px;font-size:40px;line-height:40px;border:0px;padding:0px;border-bottom: 1px solid #BEBEBE;">
                                                        &nbsp;</th>
                                                </tr>
                                                <tr>
                                                    <td class=" cell ssi_headline" align="left" valign="top"
                                                        style="border-radius: 0px 0px 0px 0px; padding:40px 0px 16px 0px; word-break:break-word; font-weight:normal">
                                                        <p
                                                            style="font-family: Arial, Helvetica, sans-serif;font-size: 24px; line-height:32px; text-align:left;color: #000000;margin:0;">
                                                            <span
                                                                style="font-family: Arial,  Helvetica,  sans-serif;color: #000000;">Get
                                                                connected with a Merck Associate</span>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr>
                                                    <td class=" cell ssi_headline" align="left" valign="top"
                                                        style="border-radius: 0px 0px 0px 0px; padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal">
                                                        <p
                                                            style="font-family: Arial, Helvetica, sans-serif;font-size: 16px; line-height:21px; text-align:left;color: #262626;margin:0;">
                                                            <span
                                                                style="font-family: Arial,  Helvetica,  sans-serif;color: #262626;">Merck
                                                                is committed to helping you get your oncology product
                                                                questions answered. Connect with a Merck Associate now
                                                                or schedule a call by visiting Ask Merck. Merck
                                                                Associates are available Monday through Friday, 8 AM to
                                                                8 PM ET.</span>
                                                        </p>
                                                    </td>
                                                </tr>

                                                <tr>
                                                    <th class="device_width spacer" height="25"
                                                        style="height:25px;font-size:25px;line-height:25px;border:0px;padding:0px;">
                                                        &nbsp;</th>
                                                </tr>
                                                <tr>
                                                    <th class="column__width--25 column__height--100 cell isNested"
                                                        align="left" valign="middle" height="30" width="100"
                                                        style="width:100px;height: 30px; padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
                                                        <table width="100%" cellspacing="0" cellpadding="0" border="0"
                                                            valign="middle" style="height:30px;text-decoration: none;">
                                                            <tr>
                                                                <td width="120" valign="middle"
                                                                    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;height: 30px; font-weight: 600;color: #006EAD; text-decoration: none !important;">
                                                                    <a href="https://www.askmerck.com?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%"
                                                                        target="_blank"
                                                                        style="text-decoration: none !important;"
                                                                        alias="Visit Ask Merck"><span valign="middle"
                                                                            style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;font-weight: 600;color: #006EAD;line-height: normal;text-decoration: none !important; width: 100px;">Visit
                                                                            Ask Merck</span></a></td>
                                                                <td width="30" align="center" valign="middle"
                                                                    style="font-family: Arial, Helvetica, sans-serif;font-size: 16px;height: 30px;line-height: normal; font-weight: 600;color: #006EAD; text-decoration: none !important;">
                                                                    <a href="https://www.askmerck.com?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%"
                                                                        target="_blank"
                                                                        style="text-decoration: none !important;"
                                                                        alias="Visit Ask Merck"><img class=""
                                                                            src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Arrow-icon.png"
                                                                            title="Arrow icon" alt="Arrow icon"
                                                                            width="20" valign="middle" border="0"
                                                                            style="font-size: 5px !important;line-height: 5px !important;"></a>
                                                                </td>
                                                                <td valign="middle" style="height: 30px;">&nbsp;</td>
                                                            </tr>
                                                        </table>
                                                    </th>
                                                    <th class="column__width--25 column__height--100 cell isNested"
                                                        align="left" valign="middle" height="30"
                                                        style="width:30px;height: 30px; padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
                                                        <table width="100%" cellspacing="0" cellpadding="0" border="0"
                                                            style="height:30px;">
                                                            <tr></tr>
                                                        </table>
                                                    </th>
                                                </tr>

                                                <tr>
                                                    <th class="device_width spacer d-none visitMerck" height="35"
                                                        style="height:35px;font-size:35px;line-height:35px;border:0px;padding:0px;">
                                                        &nbsp;</th>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </th>
                                </tr>
                            </tbody>
                        </table>
                    </th>
                </tr>
            </tbody>
        </table>
    </td>
</tr>


</tbody></table>
<table class="merck_footer device_width" width="660" cellspacing="0" cellpadding="0" border="0" align="center" style="margin:0 auto; background-color:#ffffff;"><tbody>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width spacer lnht20" height="" style="height:40px;font-size:40px;line-height:40px;border:0px;padding:0px;">&nbsp;</th></tr></tbody></table></td></tr>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 10px 0px 10px;">
<table width="340" cellspacing="0" cellpadding="0" border="0" align="center" style="margin:0 auto;"><tbody>
<tr><th class="device_width cell body_copy" align="center" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:22px; text-align:center;color: #555555;margin:0;">
&nbsp;<a href="https://www.keytrudahcp.com/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%"
alias="keytrudahcp.com" target="_blank" style="text-decoration: none;"><strong style="font-family: Arial,  Helvetica,  sans-serif;color: #006ead;"><u>keytrudahcp.com</u></strong></a>&nbsp;</p></th></tr><tr>
<td class="" align="left" valign="top" height="10" style="font-size:10px; line-height:10px;font-family:Arial, Helvetica, sans-serif;color:#555555;padding:0px;background-color: #ffffff;">&nbsp;</td></tr></tbody></table>
<table width="340" cellspacing="0" cellpadding="0" border="0" align="center" style="margin:0 auto;"><tbody>
<tr>
<th class="device_width cell body_copy" align="center" valign="top" style="border-radius: 0px 0px 0px 0px; width:540px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:22px; text-align:center;color: #555555;margin:0;">
&nbsp;<a href="https://www.askmerck.com?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%"
target="_blank" alias="Ask Merck" style="text-decoration: none;"><strong style="font-family: Arial,  Helvetica,  sans-serif;color: #006ead;"><u>Ask Merck</u></strong></a>&nbsp;</p></th></tr><tr>
<td class="" align="left" valign="top" height="10" style="font-size:10px; line-height:10px;font-family:Arial, Helvetica, sans-serif;color:#555555;padding:0px;background-color: #ffffff;">&nbsp;</td></tr></tbody></table>
<table width="340" cellspacing="0" cellpadding="0" border="0" align="center" style="margin:0 auto;"><tbody>
<tr><th class="device_width cell body_copy" align="center" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:22px; text-align:center;color: #555555;margin:0;">&nbsp;
<a href="https://www.merckaccessprogram-keytruda.com/hcp/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%" target="_blank" alias="Learn About The Merck Access Program" style="text-decoration: none;"><strong style="font-family: Arial,  Helvetica,  sans-serif;color: #006ead;"><u>Learn About&nbsp;<br>The Merck Access Program</u></strong><strong style="font-family: Arial,  Helvetica,  sans-serif;color: #006ead;">
&#00062;</strong></a>&nbsp;</p></th></tr><tr>
<td class="" align="left" valign="top" height="10" style="font-size:10px; line-height:10px;font-family:Arial, Helvetica, sans-serif;color:#555555;padding:0px;background-color: #ffffff;">&nbsp;</td></tr></tbody></table>
<table width="340" cellspacing="0" cellpadding="0" border="0" align="center" style="margin:0 auto;"><tbody>
<tr><th class="device_width cell body_copy" align="center" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 0px 0px 0px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:22px; text-align:center;color: #555555;margin:0;">&nbsp;
<a href="https://www.keytruda.com/infusion-information-and-treatment-resources/?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_content=%%emailname_%%_%%JobID%%&utm_uid=%%_subscriberkey%%" target="_blank" alias="Learn About Merck Oncology Patient Support" style="text-decoration: none;"><strong
style="font-family: Arial,  Helvetica,  sans-serif;color: #006ead;"><u>Learn About Merck Oncology Patient Support</u></strong><strong style="font-family: Arial,  Helvetica,  sans-serif;color: #006ead;"> &#00062;</strong></a>&nbsp;</p></th></tr></tbody></table></td></tr>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width spacer" height="" style="height:22px;font-size:22px;line-height:22px;border:0px;padding:0px;">&nbsp;</th></tr>
</tbody></table></td></tr>
<tr><td class="layout columns_mobile" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><td class="column__parent column__width--100 column__height--100" style="width: 660px;font-weight:normal;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><td class="column__width--100 column__height--23 cell body_copy" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 30px 0px 30px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 14px; line-height:21px; text-align:center;color: #262626;margin:0;"><span style="font-family: Arial,  Helvetica,  sans-serif;">Did you find this email helpful?</span></p></td></tr>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tbody><tr><th class="device_width spacer" height="" style="height:12px;font-size:12px;line-height:12px;border:0px;padding:0px;">&nbsp;</th></tr></tbody></table></td>
</tr>
<tr><td class="column__parent column__width--100 column__height--100">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr>
<td class="d-none" width="244">&nbsp;</td>
<td class="column__width--475 column__height--100 cell image mobile_settings mobile__align--right mobile__valign--middle isNested pr10" align="right" valign="top" width="74" height="74" style="height:74px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<a href="https://knowclick.voice-of-customers.com/5ee90458-d627-4616-a9ea-fe483925df00/email-rating.0.html?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_uid=%%_subscriberkey%%&utm_content=%%emailname_%%&utm_rating=U" target="_blank" alias="thumbs up"><img class="desktop_img wid41" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Thumbs_Up_Icon.png" title="Thumbs up" alt="Thumbs up" width="72" border="0" style="display:block; max-width:100%;font-size: 7px !important;line-height: 7px !important;"></a>
</td>
<td class="d-none" width="25">&nbsp;</td>
<td class="column__width--475 column__height--100 cell image mobile_settings mobile__align--left mobile__valign--middle isNested pl10" align="left" valign="top"  width="74" height="74" style="height:74px;padding:0px 0px 0px 0px;border-radius: 0px 0px 0px 0px;">
<a href="https://knowclick.voice-of-customers.com/5ee90458-d627-4616-a9ea-fe483925df00/email-rating.0.html?utm_source=sfmc&utm_medium=email&utm_campaign=%%campaignname%%&utm_uid=%%_subscriberkey%%&utm_content=%%emailname_%%&utm_rating=D" target="_blank" alias="thumbs down"><img class="desktop_img wid41" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/Thumbs_Down_Icon.png" title="Thumbs down" alt="Thumbs down" width="72" border="0" style="display:block; max-width:100%;font-size: 7px !important;line-height: 7px !important;"></a>
</td>
<td class="d-none" width="243">&nbsp;</td></tr></tbody></table></td></tr>
<tr><td class="" align="left" valign="top" height="22" style="font-size:22px; line-height:22px;font-family:Arial, Helvetica, sans-serif;color:#555555;padding:0px;background-color: #ffffff;">&nbsp;</td></tr>
<tr><td class="column__width--100 column__height--27 cell footer" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 30px 0px 30px; word-break:break-word; font-weight:normal;font-size: 12px;line-height: 16px;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 12px; line-height:16px; text-align:left;color: #262626;margin:0;"><strong style="font-family: Arial,  Helvetica,  sans-serif;">Clicking on this rating will result in navigation away from the Merck website and Merck content and directs to third-party content.</strong></p></td></tr></tbody></table></td></tr></tbody></table></td></tr>
<tr>
<td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody><tr><th class="device_width spacer" height="" style="height:35px;font-size:35px;line-height:35px;border:0px;padding:0px;">&nbsp;</th></tr></tbody></table></td></tr>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><th class="device_width cell footer" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 30px 0px 30px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 12px; line-height:13.2px; text-align:left;color: #262626;margin:0;">
<strong style="font-family: Arial,  Helvetica,  sans-serif;">For prescribers:
please </strong><a href="https://www.merckconnect.com/pricing-disclosures/" target="_blank" alias="click here" style="text-decoration: none;color: #006EAD;"><strong style="font-family: Arial,  Helvetica,  sans-serif;color: #006EAD;"><u>click here</u></strong></a><strong style="font-family: Arial,  Helvetica,  sans-serif;"> for state-required price disclosures.</strong></p></th></tr>
<tr><td class="" align="left" valign="top" height="12" style="font-size:12px; line-height:12px;font-family:Arial, Helvetica, sans-serif;color:#262626;padding:0px;background-color: #ffffff;">&nbsp;</td></tr></tbody></table></td></tr>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody><tr><th class="column__parent device_width" style="width: 660px;font-weight:normal;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody><tr><th class="device_width cell footer" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 30px 12px 30px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 12px; line-height:16px; text-align:left;color: #262626;margin:0;">
<span style="font-family: Arial,  Helvetica,  sans-serif;">Note:
This message was
distributed from an email account used for sending messages
only. Please do not reply to
this message.</span></p></th></tr>
<tr><th class="device_width cell footer" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 30px 0px 30px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 12px; line-height:16px; text-align:left;color: #262626;margin:0;">
<span style="font-family: Arial,  Helvetica,  sans-serif;">This
email communication is from Merck Sharp &#00038; Dohme LLC. Please manage your email
preferences or unsubscribe
anytime by clicking </span><a href="%%=Redirectto(@UnsubURL)=%%" target="_blank" alias="here" style="text-decoration: none;"><u style="font-family: Arial,  Helvetica,  sans-serif;color: #006EAD;">here</u></a><span style="font-family: Arial,  Helvetica,  sans-serif;">. If you have trouble accessing this link, please send an email to </span><a href="mailto:merck_privacy_office@merck.com?subject=Email Opt-Out Request – %%EmailName_%%" alias="merck_privacy_office@merck.com" style="text-decoration: none;color: #006EAD;"><u style="font-family: Arial, Helvetica,  sans-serif;color: #006EAD;">merck_privacy_office@merck.com</u></a><span style="font-family: Arial,  Helvetica,  sans-serif;"> with a subject line of Email Opt-Out Request &#08211; %%EmailName_%%.</span></p></th></tr>
<tr><td class="" align="left" valign="top" height="12" style="font-size:12px; line-height:12px;font-family:Arial, Helvetica, sans-serif;color:#555555;padding:0px;background-color: #ffffff;">&nbsp;</td></tr>
<tr><th class="device_width cell footer" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 30px 12px 30px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 12px; line-height:16px; text-align:left;color: #262626;margin:0;">
<span style="font-family: Arial,  Helvetica,  sans-serif;">Copyright &#00169; 2025 Merck &#00038; Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.</span>
</p></th></tr>
<tr><th class="device_width cell footer" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 30px 0px 30px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 12px; line-height:16px; text-align:left;color: #262626;margin:0;">
<span style="font-family: Arial,  Helvetica,  sans-serif;">To learn more about Merck&#08217;s commitment to privacy and your rights, please visit </span><a href="https://www.msdprivacy.com/us/en/" target="_blank" alias="merck.com/privacy" style="text-decoration: none;color: #006EAD;"><u style="font-family: Arial,  Helvetica,  sans-serif;color: #006EAD;">merck.com/privacy</u></a><span style="font-family: Arial,  Helvetica,  sans-serif;">.</span></p></th></tr>
<tr><td class="" align="left" valign="top" height="12" style="font-size:12px; line-height:12px;font-family:Arial, Helvetica, sans-serif;color:#262626;padding:0px;background-color: #ffffff;">&nbsp;</td></tr>
<tr><th class="device_width cell footer" align="left" valign="top" style="border-radius: 0px 0px 0px 0px; width:600px;padding:0px 30px 10px 30px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 12px; line-height:16px; text-align:left;color: #262626;margin:0;">
<span style="font-family: Arial,  Helvetica,  sans-serif;">Merck Privacy Office, 351 N Sumneytown Pike, UG4B-24, North Wales, PA 19454, USA</span></p></th></tr></tbody></table></th></tr></tbody></table></td></tr>
<tr><td class="layout columns" style="border-radius: 0px 0px 0px 0px;padding:0px 0px 0px 0px;">
<table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody>
<tr><td class=" cell" align="left" valign="center" height="46" style="border-radius: 0px 0px 0px 0px; width:275px;height:46px;padding:12px 30px 15px 30px; word-break:break-word; font-weight:normal;"><p style="font-family: Arial, Helvetica, sans-serif;font-size: 12px; line-height:16px; text-align:left;color: #262626;margin:0;"><span style="font-family: Arial,  Helvetica,  sans-serif;">US&zwj;-&zwj;KEY&zwj;-&zwj;091&zwj;16 01&zwj;/&zwj;25</span></p></td>
<td class=" cell image mobile_settings image__width--35 mobile__align--right mobile__valign--middle isNested" align="right" valign="middle" height="46" style="width:315px;height:46px;padding:0px 30px 15px 30px;border-radius: 0px 0px 0px 0px;"><img class="desktop_img" src="https://s3.us-east-1.amazonaws.com/com.merck.epublish/www/ghh/www.merckimages.com/US-ONCO/Email/Keytruda/US-KEY-09116/merck-logo.png" title="Merck logo" alt="Merck Logo" width="110" border="0" style="display:block; max-width:100%;font-size: 8px !important;line-height: 8px !important;">
</td></tr></tbody></table></td></tr></tbody></table>

</center>
</td></tr></tbody></table>
<div id='_two50'></div> <img id='_two50_img' src='https://2merck.everestengagement.com/ea/rL7XYGpnkw/?e=%%_SubscriberKey%%&c=%%emailname_%%' width='1' height='1' style='margin:0 !important; padding:0 !important; border:0 !important; height:1px !important; width:1px !important;' />
<custom name="opencounter" type="tracking"></custom>
</body>